

CITATION REPORT

List of articles citing

Protein kinases--the major drug targets of the twenty-first century?

DOI: 10.1038/nrd773

Nature Reviews Drug Discovery, 2002, 1, 309-15.

Source: <https://exaly.com/paper-pdf/34733690/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1813	A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. 2002 , 1, 9-19		137
1812	Death-associated protein kinase as a potential therapeutic target. 2002 , 6, 497-506		26
1811	A non-radioactive method for the assay of many serine/threonine-specific protein kinases. 2002 , 366, 977-81		34
1810	Pharmacological inhibitors of cyclin-dependent kinases. 2002 , 23, 417-25		478
1809	Bi-functional, substrate mimicking RNA inhibits MSK1-mediated cAMP-response element-binding protein phosphorylation and reveals magnesium ion-dependent conformational changes of the kinase. 2002 , 277, 45793-802		13
1808	Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. 2002 , 22, 9340-51		511
1807	Towards targeting signalling networks by functional phosphoproteomics. 2002 , 1, 169-176		3
1806	Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. 2002 , 10, 1659-67		169
1805	Protein kinase drugs--optimism doesn't wait on facts. 2002 , 7, 801-2		14
1804	Festphasensynthese von 2-Aminothiazolen unter Verwendung des spurlosen Hydrazid-Ankers: Rezeptortyrosinkinase-Inhibitoren mit dualer Selektivität für Tie-2 und VEGFR-2. 2002 , 114, 4951-4955		5
1803	Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2. 2002 , 41, 4757-61		23
1802	Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. 2002 , 9, 989-96		214
1801	The origins of protein phosphorylation. 2002 , 4, E127-30		714
1800	ATPases as drug targets: learning from their structure. <i>Nature Reviews Drug Discovery</i> , 2002 , 1, 665-73	64.1	123
1799	DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. 2002 , 1600, 128-37		37
1798	The protein kinase complement of the human genome. 2002 , 298, 1912-34		6086
1797	Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression. 2003 , 20, 411-23		7

1796	Thr94 in bovine myelin basic protein is a second phosphorylation site for 42-kDa mitogen-activated protein kinase (ERK2). 2003 , 22, 177-81	20
1795	PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design. 2003 , 55, 117-26	35
1794	Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. 2003 , 11, 399-410	103
1793	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR β -induced myeloproliferative disease. 2003 , 3, 459-69	208
1792	Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity. 2003 , 13, 3797-800	12
1791	A homogeneous, nonradioactive high-throughput fluorogenic protein kinase assay. 2003 , 317, 210-7	50
1790	CDK versus GSK-3 inhibition: a purple haze no longer?. 2003 , 10, 1144-6	19
1789	Mixed ligand complexes of platinum(II) and palladium(II) with cytokinin-derived compounds Bohemine and Olomoucine: X-ray structure of [Pt(BohH $^{+}$ -N7)Cl(3)].9/5H ₂ O [Boh=6-(benzylamino)-2-[(3-(hydroxypropyl)-amino]-9-isopropylpurine, Bohemine]. 2003 , 94, 307-16	33
1788	Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines. 2003 , 13, 2977-80	13
1787	Lead compounds discovered from libraries: part 2. 2003 , 7, 308-25	69
1786	Alternative binding modes of an inhibitor to two different kinases. 2003 , 270, 3174-81	65
1785	p38 Mitogen-activated protein kinases on the body surface--a function for p38 delta. 2003 , 120, 823-8	78
1784	Chemical proteomics and its application to drug discovery. 2003 , 14, 87-95	191
1783	Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A. 2003 , 10, 443-51	39
1782	Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. 2003 , 125, 1144-5	191
1781	Chapter 20. Beyond kinases: Purine-binding enzymes as cancer targets. 2003 , 38, 193-202	4
1780	Kinase inhibitors: not just for kinases anymore. 2003 , 46, 1478-83	231
1779	Chemical approaches to reversible protein phosphorylation. 2003 , 36, 444-52	23

1778	STI-571: an anticancer protein-tyrosine kinase inhibitor. 2003 , 309, 709-17	83
1777	Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). 2003 , 329, 1021-34	47
1776	PTP1B: from the sidelines to the front lines!. 2003 , 546, 140-8	266
1775	UV-light induces p38 MAPK-dependent phosphorylation of Bcl10. 2003 , 301, 923-6	16
1774	M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. 2003 , 306, 880-6	6
1773	Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. 2003 , 193, 161-70	80
1772	High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases. 2003 , 1, 445-53	41
1771	Generation of bis-cationic heterocyclic inhibitors of Bacillus subtilis HPr kinase/phosphatase from a ditopic dynamic combinatorial library. 2003 , 46, 5803-11	57
1770	CDK inhibitors in clinical development for the treatment of cancer. 2003 , 12, 955-70	99
1769	Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. 2003 , 36, 417-25	309
1768	MAPKs: new targets for neurodegeneration. 2003 , 7, 187-200	88
1767	A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. 2003 , 8, 447-52	31
1766	Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. 2003 , 372, 1-13	286
1765	The specificities of protein kinase inhibitors: an update. 2003 , 371, 199-204	1241
1764	An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. 2003 , 100, 15434-9	317
1763	Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. 2003 , 278, 1831-6	65
1762	Identification of novel phosphorylation sites on Xenopus laevis Aurora A and analysis of phosphopeptide enrichment by immobilized metal-affinity chromatography. 2003 , 2, 1055-67	113
1761	The ATPases: a new family for a family-based drug design approach. 2003 , 7, 453-61	9

1760	Fluorescence assays for high-throughput screening of protein kinases. 2003 , 6, 313-20	41
1759	Organische Chemie 2002. 2003 , 51, 286-315	3
1758	Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery. 2003 , 8, 349-358	5
1757	Novel Protein Kinase Inhibitors: SMART Drug Design Technology. 2003 , 34, S2-S15	12
1756	Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. 2004 , 5, 69-77	34
1755	Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. 2004 , 5, 1671-86	33
1754	Inhibitors of cellular signaling targets: designs and limitations. 2004 , 273, 87-102	2
1753	Substrate capacity considerations in developing kinase assays. 2004 , 2, 131-40	7
1752	Two simple and generic antibody-independent kinase assays: comparison of a bioluminescent and a microfluidic assay format. 2004 , 9, 409-16	30
1751	Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase. 2004 , 9, 309-21	11
1750	A homogeneous, nonradioactive high-throughput fluorogenic protein phosphatase assay. 2004 , 9, 223-31	19
1749	Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). 2004 , 279, 50401-9	113
1748	Purification and identification of protein-tyrosine kinase-binding proteins using synthetic phosphopeptides as affinity reagents. 2004 , 3, 887-95	5
1747	Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. 2004 , 3, 1181-93	69
1746	Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. 2004 , 109, 1196-205	114
1745	The mouse kinome: discovery and comparative genomics of all mouse protein kinases. 2004 , 101, 11707-12	248
1744	Metal ion-mediated polymer superquenching for highly sensitive detection of kinase and phosphatase activities. 2004 , 101, 15295-300	129
1743	Identification of kinase inhibitors by an ATP depletion method. 2004 , 2, 161-9	34

1742	Evaluation of kinase inhibitor selectivity by chemical proteomics. 2004 , 2, 215-24	42
1741	Cholesterol depletion upregulates involucrin expression in epidermal keratinocytes through activation of p38. 2004 , 123, 564-73	59
1740	Regulating the beat. <i>Nature Reviews Drug Discovery</i> , 2004 , 3, 203-203	64.1
1739	Strategies to overcome resistance to targeted protein kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2004 , 3, 1001-10	64.1 276
1738	Targeting protein kinases. <i>Nature Reviews Drug Discovery</i> , 2004 , 3, 993-4	64.1 92
1737	Identifying protein kinase substrates: hunting for the organ-grinder's monkeys. 2004 , 29, 227-32	45
1736	Strategies for drug discovery by targeting sulfation pathways. 2004 , 9, 967-75	39
1735	Protein kinases of the human malaria parasite <i>Plasmodium falciparum</i> : the kinome of a divergent eukaryote. 2004 , 5, 79	376
1734	Tyrosine kinase receptors as attractive targets of cancer therapy. 2004 , 50, 23-38	140
1733	Protein kinase inhibitors: insights into drug design from structure. 2004 , 303, 1800-5	1035
1732	Development of high-throughput screens for discovery of kinesin adenosine triphosphatase modulators. 2004 , 329, 68-76	29
1731	Protein kinase inhibitors: novel tools in cancer therapy. 2004 , 43 Suppl 3, S148	
1730	Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. 2004 , 40, 459-66	70
1729	Screening of natural compounds and their derivatives as potential protein kinase C inhibitors. 2004 , 63, 76-87	21
1728	MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. 2004 , 112, 986-93	50
1727	Enzymatic desymmetrization of 5-bis(hydroxymethyl)tetrahydro-2-furanone: a template for protein kinase C ligands. 2004 , 15, 863-866	12
1726	Isolation of phosphopeptides using solid phase enrichment. 2004 , 45, 91-93	24
1725	Protein kinases as targets for anti-parasitic chemotherapy. 2004 , 1697, 155-68	103

1724	Meridianins, a new family of protein kinase inhibitors isolated from the ascidian <i>Aplidium meridianum</i> . 2004 , 14, 1703-7	166
1723	Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles. 2004 , 14, 2155-8	16
1722	Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A. 2004 , 14, 2951-4	30
1721	Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next generation of drugs for severe asthma and COPD?. 2004 , 18, 167-80	14
1720	Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors. 2004 , 19, 585-93	6
1719	Platelets and Megakaryocytes. 2004 ,	4
1718	Optimal Length and Signal Amplification in Weakly Activated Signal Transduction Cascades. 2004 , 108, 15311-15320	43
1717	Detection of phosphorylated peptides in proteomic analyses using microfluidic compact disk technology. 2004 , 76, 5864-71	51
1716	Polyprenyl-hydroquinones and -furans from three marine sponges inhibit the cell cycle regulating phosphatase CDC25A. 2004 , 18, 1-9	21
1715	Network-targeted combination therapy: a new concept in cancer treatment. 2004 , 1, 425-433	12
1714	Novel Anti-inflammatory Therapies. 2004 , 349-372	
1713	Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. 2004 , 47, 1962-8	121
1712	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. 2004 , 47, 935-46	308
1711	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. 2004 , 13, 1-19	46
1710	Recent advances towards identification of new drug targets for <i>Mycobacterium tuberculosis</i> . 2004 , 8, 79-93	20
1709	Pharmacological inhibitors of glycogen synthase kinase 3. 2004 , 25, 471-80	510
1708	Is JAK3 a new drug target for immunomodulation-based therapies?. 2004 , 25, 558-62	30
1707	Toward a pharmacophore for kinase frequent hitters. 2004 , 47, 5616-9	55

1706	Gains and optimal design in signaling pathways. 2004,	
1705	Mechanism targeted discovery of antitumor marine natural products. 2004, 11, 1725-56	60
1704	Protein Kinase Inhibitors Drug Discovery. 2005, 1191-1257	4
1703	Translating MAPK Inhibitors To Anti-Inflammatory Compounds. 2005, 1, 75-84	1
1702	Posttranslational protein modifications. 2005, 33, S407-9	25
1701	Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. 2005, 70, 499-515	24
1700	Introduction to the Kinases in Diabetes Biochemical Society Focused Meeting: are protein kinases good targets for antidiabetic drugs?. 2005, 33, 339-42	4
1699	Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. 2005, 12, 1211-9	104
1698	Pyrazolylbenzoxazole derivatives as protein kinase inhibitors. Design and validation of a combinatorial library. 2005, 61, 10801-10810	14
1697	New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties. 2005, 15, 135-8	55
1696	Discovery, synthesis and biological evaluation of novel glucokinase activators. 2005, 15, 2103-6	48
1695	Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines. 2005, 15, 3778-81	29
1694	In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. 2005, 15, 5207-10	69
1693	Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives. 2005, 15, 5129-35	36
1692	Fluorometric TLC assay for evaluation of protein kinase inhibitors. 2005, 340, 165-70	22
1691	Features of selective kinase inhibitors. 2005, 12, 621-37	509
1690	Peptide inhibitors of protein kinases-discovery, characterisation and use. 2005, 1754, 79-99	56
1689	Characterisation of kinase-selective inhibitors by chemical proteomics. 2005, 1754, 183-90	32

1688	Features and potentials of ATP-site directed CK2 inhibitors. 2005 , 1754, 263-70	57
1687	Protein kinase structure and function analysis with chemical tools. 2005 , 1754, 65-78	45
1686	Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. 2005 , 1754, 132-50	70
1685	Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: molecular yardsticks for analyzing catalytic mechanism and inhibitor design. 2005 , 33, 285-97	21
1684	Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. 2005 , 48, 121-33	96
1683	Protein kinase signaling cascades in CNS trauma. 2005 , 57, 711-8	29
1682	A small molecule-kinase interaction map for clinical kinase inhibitors. 2005 , 23, 329-36	1569
1681	Calmodulin kinase II inhibition protects against structural heart disease. 2005 , 11, 409-17	465
1680	The evolving role of natural products in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2005 , 4, 206-20	64.1 1678
1679	Assay development: an increasingly creative endeavour. <i>Nature Reviews Drug Discovery</i> , 2005 , 4, 1027	64.1 3
1678	Reconstruction of cellular signalling networks and analysis of their properties. 2005 , 6, 99-111	408
1677	Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. 2005 , 25, 91-103	49
1676	Tyrosine phosphorylation in mitochondria: a new frontier in mitochondrial signaling. 2005 , 38, 1267-77	93
1675	Chemical approaches for investigating phosphorylation in signal transduction networks. 2005 , 15, 502-10	120
1674	Characterization of two <i>T. gondii</i> CK1 isoforms. 2005 , 141, 15-27	30
1673	Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. 2005 , 5, 125	11
1672	Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2. 2005 , 43, 320-6	32
1671	Biochemical applications of mass spectrometry in pharmaceutical drug discovery. 2005 , 24, 347-66	67

1670	Structure-aided optimization of kinase inhibitors derived from alsterpaullone. 2005 , 6, 541-9	35
1669	Classifying "kinase inhibitor-likeness" by using machine-learning methods. 2005 , 6, 558-66	40
1668	Kinase data mining: dealing with the information (over-)flow. 2005 , 6, 567-70	
1667	High-throughput screening for kinase inhibitors. 2005 , 6, 481-90	106
1666	Small-molecule kinase-inhibitor target assessment. 2005 , 6, 523-6	20
1665	Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. 2005 , 6, 1607-10	23
1664	A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. 2005 , 338, 136-42	68
1663	Evidence for proximal cysteine and lysine residues at or near the active site of arginine kinase of <i>Stichopus japonicus</i> . 2005 , 70, 24-39	
1662	Molecular mechanisms of hormonal activity. I. receptors. neuromediators. systems with second messengers. 2005 , 70, 24-39	0
1661	High-throughput kinase assays with protein substrates using fluorescent polymer superquenching. 2005 , 5, 16	11
1660	Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex. 2006 , 62, 89-98	16
1659	Mapping of phosphorylation sites of nuclear corepressor receptor interacting protein 140 by liquid chromatography-tandem mass spectroscopy. 2005 , 5, 2157-66	25
1658	Tandem mass spectrometry of multiply phosphorylated forms of a 'histidine-tag' derived from a recombinant protein kinase expressed in bacteria. 2005 , 19, 547-51	5
1657	Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems. 2005 , 1-7	
1656	A NIMA-related protein kinase is essential for completion of the sexual cycle of malaria parasites. 2005 , 280, 31957-64	111
1655	Mitotic kinesins: prospects for antimetabolic drug discovery. 2005 , 5, 127-45	118
1654	Synthesis and evaluation of the antiproliferative activity of novel thiazoloquinazolinone kinase inhibitors. 2005 , 20, 557-68	27
1653	Roscovitine targets, protein kinases and pyridoxal kinase. 2005 , 280, 31208-19	278

1652	Characterization of an ERK-binding domain in microphthalmia-associated transcription factor and differential inhibition of ERK2-mediated substrate phosphorylation. 2005 , 280, 42051-60	28
1651	An evolutionary proteomics approach identifies substrates of the cAMP-dependent protein kinase. 2005 , 102, 13933-8	183
1650	A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors. 2005 , 10, 447-55	17
1649	Regulation of co-repressive activity of and HDAC recruitment to RIP140 by site-specific phosphorylation. 2005 , 4, 1776-84	42
1648	Development of a microplate-based, electrophoretic fluorescent protein kinase assay: comparison with filter-binding and fluorescence polarization assay formats. 2005 , 10, 329-38	8
1647	Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. 2005 , 65, 4870-80	118
1646	The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3. 2005 , 47-64	5
1645	Chapter 13 Targeting the Kinome with Computational Chemistry. 2005 , 185-202	2
1644	The transcription factor NF-kappaB as drug target. 2005 , 43, 137-88	9
1643	Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes. 2005 , 280, 27728-41	53
1642	Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. 2005 , 280, 13728-34	147
1641	Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. 2005 , 65, 2854-60	79
1640	Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. 2005 , 102, 3587-92	50
1639	Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase. 2005 , 280, 21384-93	14
1638	Selective activation of the MEK-ERK pathway is regulated by mechanical stimuli in forming joints and promotes pericellular matrix formation. 2005 , 280, 11749-58	44
1637	New pharmacological treatment approaches for anxiety disorders. 2005 , 503-26	2
1636	Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors. 2005 , 215-262	2
1635	Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway. 2005 , 4, 310-27	665

1634	Specificity of immobilized metal affinity-based IMAC/C18 tip enrichment of phosphopeptides for protein phosphorylation analysis. 2005 , 77, 5144-54	190
1633	The synthesis of bioactive indolocarbazoles related to K-252a. 2005 , 3, 2953-75	15
1632	Design and synthesis of inositolphosphoglycan putative insulin mediators. 2005 , 3, 764-86	16
1631	Lanthanide-mediated phosphoester hydrolysis and phosphate elimination from phosphopeptides. 2005 , 5426-8	13
1630	Second-generation kinase inhibitors. 2005 , 9, 975-93	48
1629	Genomics and the second golden era of cancer drug development. 2005 , 1, 17-26	43
1628	Using bioinformatics for drug target identification from the genome. 2005 , 5, 387-96	25
1627	Real-time protein kinase assay. 2005 , 77, 2043-9	24
1626	Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. 2005 , 48, 163-70	54
1625	Cluster-phase reactions: gas-phase phosphorylation of peptides and model compounds with triphosphate anions. 2005 , 127, 4084-90	16
1624	Scale-free networks in cell biology. 2005 , 118, 4947-57	812
1623	Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. 2005 , 44, 16475-90	85
1622	Regulation of the wild-type and Y1235D mutant Met kinase activation. 2005 , 44, 14110-9	9
1621	Identification of a molecular recognition role for the activation loop phosphotyrosine of the SRC tyrosine kinase. 2005 , 127, 1600-1	6
1620	Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. 2005 , 352, 918-31	82
1619	High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. 2005 , 352, 1134-56	38
1618	Spatial restriction of PDK1 activation cascades by anchoring to mAKAPalpha. 2005 , 20, 661-72	59
1617	Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. 2005 , 338, 1307-15	246

1616	DAP-kinase--protector or enemy in apoptotic cell death. 2005 , 37, 1763-7	20
1615	Improved yields for baculovirus-mediated expression of human His(6)-PDK1 and His(6)-PKBbeta/Akt2 and characterization of phospho-specific isoforms for design of inhibitors that stabilize inactive conformations. 2005 , 43, 44-56	13
1614	Phosphorylation of serine residues in histidine-tag sequences attached to recombinant protein kinases: a cause of heterogeneity in mass and complications in function. 2005 , 44, 121-9	22
1613	Screening of protein kinases by ATP-STD NMR spectroscopy. 2005 , 127, 7978-9	45
1612	Yeast growth selection system for detecting activity and inhibition of dimerization-dependent receptor tyrosine kinase. 2005 , 39, 541-9	21
1611	Phospho-specific flow cytometry in drug discovery. 2005 , 2, 295-302	10
1610	Rapid computational identification of the targets of protein kinase inhibitors. 2005 , 48, 4138-52	45
1609	Inhibitors of Protein Kinase CK2: Structural Aspects. 2005 , 125-155	4
1608	Nanoliter homogenous ultra-high throughput screening microarray for lead discoveries and IC50 profiling. 2005 , 3, 177-87	35
1607	DNA Methyltransferase Inhibitors. 2005 , 187-204	
1606	Intracellular signal transduction pathway proteins as targets for cancer therapy. 2005 , 23, 5386-403	155
1605	Microarray-based detection of protein binding and functionality by gold nanoparticle probes. 2005 , 77, 5770-4	146
1604	Virtual screening of 4-anilinoquinazoline analogues as EGFR kinase inhibitors: importance of hydrogen bonds in the evaluation of poses and scoring functions. 2005 , 45, 725-38	44
1603	Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. 2005 , 11, 1-68	45
1602	Bioinformatics and Drug Discovery. 2006 ,	1
1601	Kinase-catalyzed modification of gold nanoparticles: a new approach to colorimetric kinase activity screening. 2006 , 128, 2214-5	252
1600	Reactivity and biological activity of the marine sesquiterpene hydroquinone avarol and related compounds from sponges of the order Dictyoceratida. 2006 , 11, 1-33	53
1599	Host cell targets for antiviral therapy: an update. 2006 , 1, 509-518	2

1598	Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. 2006 , 10, 67-76	32
1597	Proteomics technology in systems biology. 2006 , 2, 364-70	34
1596	A priori inference of cross reactivity for drug-targeted kinases. 2006 , 49, 3092-100	28
1595	Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells. 2006 , 98, 1367-79	17
1594	Case histories, magic bullets and the state of drug discovery. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 635-40	64.1 34
1593	Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. 2006 , 23, 1007-45	305
1592	Biochemical Assays for High-throughput Screening. 2006 , 93-128	3
1591	Real-time analysis of enzyme kinetics via micro parallel liquid chromatography. 2006 , 4, 653-60	12
1590	Proteomic approaches in drug discovery. 2006 , 3, 433-440	12
1589	Reading dynamic kinase activity in living cells for high-throughput screening. 2006 , 1, 371-6	97
1588	Concise strategy to the core structure of the macrolide queenslandon. 2006 , 8, 5833-6	19
1587	Transcreener: screening enzymes involved in covalent regulation. 2006 , 10, 179-90	36
1586	Discovery of protein phosphatase 2C inhibitors by virtual screening. 2006 , 49, 1658-67	60
1585	Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. 2006 , 49, 7150-9	53
1584	The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria. 2006 , 580, 3018-22	87
1583	Mechanisms of gamma-glutamylcysteine ligase regulation. 2006 , 1760, 233-44	40
1582	Biophysical characterization of an indolinone inhibitor in the ATP-binding site of DNA gyrase. 2006 , 349, 1206-13	14
1581	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 2006 , 237, 89-94	39

1580	Nek2 kinase in chromosome instability and cancer. 2006 , 237, 155-66	125
1579	From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. 2006 , 359, 1023-44	79
1578	The sea urchin kinome: a first look. 2006 , 300, 180-93	74
1577	Analyzing protein kinase dynamics in living cells with FRET reporters. 2006 , 40, 279-86	65
1576	CRF signaling: molecular specificity for drug targeting in the CNS. 2006 , 27, 531-8	84
1575	Protein kinase CK2: a newcomer in the 'druggable kinome'. 2006 , 34, 1303-6	62
1574	Characterization of the reversible phosphorylation and activation of ERK8. 2006 , 394, 365-73	47
1573	Investigating the molecular basis of drug action and response: chemocentric genomics and proteomics. 2006 , 7, 387-95	5
1572	Current status of virtual screening as analysed by target class. 2006 , 2, 89-112	21
1571	SIFT: Analysis, Organization and Database Mining for Protein-Inhibitor Complexes. Application to Protein Kinase Inhibitors. 2006 , 207-222	
1570	Construction of a Homogeneous and Informative In vitro Profiling Database for Anticipating the Clinical Effects of Drugs. 2006 , 175-206	6
1569	Ringling the alarm bells: signalling and apoptosis in influenza virus infected cells. 2006 , 8, 375-86	184
1568	Structural study of the catalytic domain of PKCzeta using infrared spectroscopy and two-dimensional infrared correlation spectroscopy. 2006 , 273, 3273-86	9
1567	A kinase-focused compound collection: compilation and screening strategy. 2006 , 67, 385-94	15
1566	Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening. 2006 , 68, 154-65	10
1565	Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in <i>Streptococcus agalactiae</i> . 2006 , 62, 941-57	85
1564	Rational design of inhibitors that bind to inactive kinase conformations. 2006 , 2, 358-64	854
1563	Small molecule-based reversible reprogramming of cellular lifespan. 2006 , 2, 369-74	54

1562	New approaches to molecular cancer therapeutics. 2006 , 2, 689-700	307
1561	Assay of protein kinases using radiolabeled ATP: a protocol. 2006 , 1, 968-71	185
1560	Pharmacology of intracellular signalling pathways. 2006 , 147 Suppl 1, S38-45	3
1559	Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. 2006 , 25, 5469-80	88
1558	RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. 2006 , 25, 1340-8	52
1557	7-Bromoindirubin-3'-oxime induces caspase-independent cell death. 2006 , 25, 6304-18	85
1556	Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. 2006 , 41, 296-305	85
1555	3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors. 2006 , 41, 1310-9	34
1554	Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK. 2006 , 14, 6034-42	29
1553	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. 2006 , 16, 3419-23	51
1552	Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization. 2006 , 350, 268-76	23
1551	Optimal Sox-based fluorescent chemosensor design for serine/threonine protein kinases. 2006 , 352, 198-207	62
1550	Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. 2006 , 356, 273-81	66
1549	Feature-similarity protein classifier as a ligand engineering tool. 2006 , 23, 307-15	8
1548	Selective kinase inhibition by exploiting differential pathway sensitivity. 2006 , 13, 399-407	19
1547	A general strategy for creating "inactive-conformation" abl inhibitors. 2006 , 13, 779-86	132
1546	Catch the kinase conformer. 2006 , 13, 693-4	7
1545	Protein kinases as potential targets for the treatment of pathological pain. 2007 , 359-89	63

1544	Selectivity and potency of cyclin-dependent kinase inhibitors. 2006 , 8, E204-21	49
1543	Antimalarial drugs - host targets (re)visited. 2006 , 1, 321-32	35
1542	FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. 2006 , 25, 147-51	55
1541	CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction. 2007 , 85, 5-14	47
1540	Mapping the bound conformation and protein interactions of microtubule destabilizing peptides by STD-NMR spectroscopy. 2006 , 16, 4279-82	9
1539	Protein kinases and phosphatases as therapeutic targets in cancer. 2006 , 8, 153-60	65
1538	Natural compounds from Danshen suppress the activity of hepatic stellate cells. 2006 , 29, 762-7	7
1537	Agents against cytokine synthesis or receptors. 2006 , 533, 289-301	32
1536	Kinase inhibitors and airway inflammation. 2006 , 533, 118-32	108
1535	Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. 2006 , 16, 1366-72	171
1534	Chemogenomics: structuring the drug discovery process to gene families. 2006 , 11, 880-8	65
1533	Emerging applications for phospho-proteomics in cancer molecular therapeutics. 2006 , 1766, 230-41	12
1532	Lining the pockets of kinases and phosphatases. 2006 , 16, 693-701	66
1531	Charging it up: global analysis of protein phosphorylation. 2006 , 22, 545-54	116
1530	Novel signal transduction modulators for the treatment of airway diseases. 2006 , 109, 238-45	46
1529	Diversity-oriented synthesis of pochonins and biological evaluation against a panel of kinases. 2006 , 12, 8819-34	36
1528	Can MM-PBSA calculations predict the specificities of protein kinase inhibitors?. 2006 , 27, 1990-2007	49
1527	The role of mass spectrometry in plant systems biology. 2006 , 25, 173-214	123

1526	Discovering new drug-targeting sites on flexible multidomain protein kinases: Combining segmental isotopic and site-directed spin labeling for nuclear magnetic resonance detection of interfacial clefts. 2006 , 316, 199-225	2
1525	Using substrate-binding variants of the cAMP-dependent protein kinase to identify novel targets and a kinase domain important for substrate interactions in <i>Saccharomyces cerevisiae</i> . 2006 , 173, 1909-17	45
1524	Targeting cancer: the challenges and successes of structure-based drug design against the human purinome. 2006 , 6, 1129-59	16
1523	Protein kinases as drug targets in cancer. 2006 , 6, 623-34	68
1522	The use of anticancer drugs in antiparasitic chemotherapy. 2006 , 6, 131-43	43
1521	Computational approaches to model ligand selectivity in drug design. 2006 , 6, 41-55	34
1520	Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. 2006 , 11, 617-33	40
1519	Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). 2006 , 7, 159-70	6
1518	Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. 2006 , 15, 23-38	28
1517	Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. 2006 , 70, 1061-95	417
1516	Overview. 2006 , 1-17	1
1515	Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates. 2006 , 11, 1015-26	25
1514	Molecular identification and characterization of a family of kinases with homology to Ca ²⁺ /calmodulin-dependent protein kinases I/IV. 2006 , 281, 20427-39	36
1513	Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). 2006 , 5, 1610-27	72
1512	Assay development and screening of a serine/threonine kinase in an on-chip mode using caliper nanofluidics technology. 2006 , 11, 359-68	54
1511	Comparison of kinome profiles of Barrett's esophagus with normal squamous esophagus and normal gastric cardia. 2006 , 66, 11605-12	68
1510	Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. 2006 , 17, 2434-42	74
1509	A specific mechanomodulatory role for p38 MAPK in embryonic joint articular surface cell MEK-ERK pathway regulation. 2006 , 281, 11011-8	27

1508	The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth. 2006 , 188, 7778-84	150
1507	Kinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1. 2006 , 11, 755-64	27
1506	Phosphoproteomics: Challenges and Opportunities. 2006 , 3, 249-257	3
1505	Phospho-Specific Antibodies: A Versatile Tool for Phosphoproteomic Studies. 2006 , 3, 113-117	
1504	Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease. 2006 , 3, 437-45	22
1503	Kinesin spindle protein Inhibitors as anticancer agents. 2006 , 16, 1517-1532	20
1502	Overcoming the hurdle of fluorescent compounds in kinase screening: a case study. 2006 , 4, 185-96	11
1501	Microarrays for the functional analysis of the chemical-kinase interactome. 2006 , 11, 48-56	38
1500	Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. 2007 , 282, 19808-19	27
1499	Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. 2007 , 6, 1877-85	49
1498	Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. 2007 , 104, 16916-21	158
1497	Kinase-dependent pathways and the development of insulin resistance in hepatocytes. 2007 , 2, 195-203	1
1496	Malignant glioma drug discovery - targeting protein kinases. 2007 , 2, 1-17	18
1495	Structure-based approaches in the design of GSK-3 selective inhibitors. 2007 , 8, 352-64	22
1494	Protein kinases as small molecule inhibitor targets in inflammation. 2007 , 14, 2214-34	79
1493	The role of halogen bonding in inhibitor recognition and binding by protein kinases. 2007 , 7, 1336-48	142
1492	Modulating drug impact by wrapping target proteins. 2007 , 2, 249-59	1
1491	Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. 2007 , 383-405	4

1490	Designing in vitro assays for drug discovery: a study with the human MAP3 kinase COT. 2007 , 2, 909-15	2
1489	Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. 2007 , 18 Suppl 6, vi22-5	19
1488	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. 2007 , 959-992	2
1487	Synthesis and characterization of 5'-p-fluorosulfonylbenzoyl-2' (or 3')-(biotinyl)adenosine as an activity-based probe for protein kinases. 2007 , 12, 126-32	13
1486	Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity. 2007 , 35, 972-83	13
1485	Optimizing Kinase Assays for Ultrahigh-Throughput Profiling using the Kinase-Glo plus Assay. 2007 , 12, 99-103	5
1484	Characterization of a UBC13 kinase in Plasmodium falciparum. 2007 , 104, 7845-50	23
1483	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. 2007 , 104, 20523-8	286
1482	Label-free kinase profiling using phosphate affinity polyacrylamide gel electrophoresis. 2007 , 6, 356-66	114
1481	Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. 2007 , 321, 35-44	55
1480	A peptide microarray for the detection of protein kinase activity in cell lysate. 2007 , 23, 271-5	36
1479	Subject Index To Volume 5. 2007 , 6, 3-6	
1478	Editorial [Hot Topic: Kinase Targets and Inhibitors in Inflammation (Guest Editors: Khusru Asadullah and Matthias Gaestel)]. 2007 , 6, 1-1	
1477	Regulation of positive-strand RNA virus replication: the emerging role of phosphorylation. 2007 , 129, 73-9	66
1476	Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). 2007 , 34, 153-63	57
1475	An intrinsic ATPase activity of phospho-MEK-1 uncoupled from downstream ERK phosphorylation. 2007 , 464, 130-7	17
1474	Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53. 2007 , 358, 181-8	34
1473	Detection of in vitro kinase generated protein phosphorylation sites using gamma[18O4]-ATP and mass spectrometry. 2007 , 79, 7603-10	23

1472	Antimalarial drug discovery: targeting protein kinases. 2007 , 11, 279-90	65
1471	Inhibiting kinases in malignant gliomas. 2007 , 11, 473-96	34
1470	Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. 2007 , 25, 1035-44	864
1469	Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery. 2007 ,	1
1468	FRET-based biosensors for protein kinases: illuminating the kinome. 2007 , 3, 759-65	109
1467	Electrochemical detection of kinase-catalyzed thiophosphorylation using gold nanoparticles. 2007 , 5019-21	45
1466	Bioactive constituents from the marine crinoid <i>Himerometra magnipinna</i> . 2007 , 70, 869-71	21
1465	Large-scale phosphorylation analysis of alpha-factor-arrested <i>Saccharomyces cerevisiae</i> . 2007 , 6, 1190-7	260
1464	Microarray-based kinase inhibition assay by gold nanoparticle probes. 2007 , 79, 773-7	53
1463	Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data. 2007 , 47, 1319-27	57
1462	A pharmacophore map of small molecule protein kinase inhibitors. 2007 , 47, 2374-82	37
1461	Lemnalsides A-D, decalin-type bicyclic diterpene glycosides from the marine soft coral <i>Lemnalia</i> sp. 2007 , 70, 901-5	22
1460	Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains. 2007 , 18, 1294-302	10
1459	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. 2007 , 50, 4027-37	55
1458	A 10,000 member PNA-encoded peptide library for profiling tyrosine kinases. 2007 , 2, 810-8	31
1457	Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. 2007 , 50, 409-24	416
1456	Exploited defense: how influenza viruses take advantage of antiviral signaling responses. 2007 , 2, 91-100	15
1455	Protein kinases as targets for cancer treatment. 2007 , 8, 1005-16	60

1454	NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor. 2007 , 2, 117739010700200	17
1453	Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview. 2007 , 6, 3-4	1
1452	Structural Aspects of Drugability and Selectivity of Protein Kinases in Inflammation. 2007 , 6, 5-17	7
1451	High Throughput Screening in Agrochemical Research. 1139-1159	
1450	Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. 2007 , 8, 129-39	104
1449	Measurement of homogeneous kinase activity for cell lysates based on the aggregation of gold nanoparticles. 2007 , 8, 875-9	71
1448	The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. 2007 , 8, 1804-9	86
1447	Europium tetracycline as a luminescent probe for nucleoside phosphates and its application to the determination of kinase activity. 2007 , 13, 4342-9	114
1446	Computational study of the phosphoryl transfer catalyzed by a cyclin-dependent kinase. 2007 , 13, 8437-44	43
1445	Phosphate recognition in structural biology. 2007 , 46, 338-52	229
1444	Involvement of protein kinase Czeta in interleukin-1beta induction of ADAMTS-4 and type 2 nitric oxide synthase via NF-kappaB signaling in primary human osteoarthritic chondrocytes. 2007 , 56, 4074-83	29
1443	Molekulare Erkennung von Phosphaten in der Strukturbiologie. 2007 , 119, 342-357	33
1442	Functional classification of protein kinase binding sites using Cavbase. 2007 , 2, 1432-47	57
1441	A highly selective Ir-catalyzed borylation of 2-substituted indoles: a new access to 2,7- and 2,4,7-substituted indoles. 2007 , 48, 371-375	37
1440	Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. 2007 , 17, 3880-5	37
1439	Carbocyclic 3'-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. 2007 , 17, 5336-9	15
1438	Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening. 2007 , 128, 165-75	19
1437	3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity. 2007 , 42, 1014-27	36

1436	Surface-plasmon-resonance-based biosensor with immobilized bisubstrate analog inhibitor for the determination of affinities of ATP- and protein-competitive ligands of cAMP-dependent protein kinase. 2007 , 362, 268-77	34
1435	An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1. 2007 , 367, 179-89	9
1434	An integrated procedure of selective injection, sample stacking and fractionation of phosphopeptides for MALDI MS analysis. 2007 , 581, 268-80	23
1433	Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. 2007 , 15, 702-13	25
1432	Chemical proteomics for drug discovery based on compound-immobilized affinity chromatography. 2007 , 855, 21-7	28
1431	3D-QSAR CoMFA Study on Aminothiazole Derivatives as Cyclin-Dependent Kinase 2 Inhibitors. 2007 , 26, 85-91	11
1430	Influenza viruses and MAP kinase cascades [Novel targets for an antiviral intervention?]. 2007 , 7, 81-88	17
1429	Classification and functional annotation of eukaryotic protein kinases. 2007 , 68, 893-914	121
1428	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. 2007 , 3, 229-38	168
1427	The reverse in-gel kinase assay to profile physiological kinase substrates. 2007 , 4, 957-62	14
1426	Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 617-35	64.1 119
1425	Emerging roles of nuclear protein phosphatases. 2007 , 8, 234-44	293
1424	PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. 2007 , 26, 505-15	47
1423	Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. 2007 , 150, 200-8	44
1422	Two New Coumarins from <i>Fraxinus chinensis</i> Rehb.. 2007 , 49, 218-221	1
1421	The complement of protein kinases of the microsporidium <i>Encephalitozoon cuniculi</i> in relation to those of <i>Saccharomyces cerevisiae</i> and <i>Schizosaccharomyces pombe</i> . 2007 , 8, 309	59
1420	Regulatory mechanisms underlying GKR2 levels in U937 cells: evidence for GRK3 involvement. 2007 , 73, 1758-67	3
1419	Initial three-dimensional reconstructions of protein kinase C delta from two-dimensional crystals on lipid monolayers. 2007 , 19, 2035-45	8

1418	Insights for the development of specific kinase inhibitors by targeted structural genomics. 2007 , 12, 365-72	57
1417	Mechanisms underlying the inhibitory actions of the pentacyclic triterpene alpha-amyrin in the mouse skin inflammation induced by phorbol ester 12-O-tetradecanoylphorbol-13-acetate. 2007 , 559, 227-35	87
1416	Nuevas perspectivas terapéuticas farmacológicas en el manejo de la EPOC. 2007 , 43, 27-35	
1415	Editorial: role of cyclin-dependent kinase-5 (Cdk5) in the central nervous system. 2007 , 2, 914-5	3
1414	Cyclin-Dependent Kinase 5. 2006 , 81-100	
1413	The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. 2007 , 8, 107-19	55
1412	Homology models of the mutated EGFR and their response towards quinazoline analogues. 2008 , 27, 244-54	9
1411	Protein phosphatases and cancer. Preface. 2008 , 27, 121-2	2
1410	A cell-based screening method for specifically detecting kinase activity. 2008 , 390, 343-8	2
1409	Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. 2008 , 466, 2168-75	39
1408	Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study. 2008 , 34, 617-33	43
1407	Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein microarrays. 2008 , 8, 1980-6	33
1406	[The short history of protein kinase inhibitors. New, competitive, successful]. 2008 , 37, 360-8	4
1405	[Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research]. 2008 , 37, 382-92	1
1404	Total synthesis of (-)-balanol, all stereoisomers, their N-tosyl analogues, and fully protected opiocordin: an easy route to hexahydroazepine cores from Garner aldehydes. 2008 , 14, 4675-88	52
1403	Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. 2008 , 3, 435-44	251
1402	Small-molecule inhibitors of PDK1. 2008 , 3, 1810-38	96
1401	Src-Tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation. 2008 , 104, 840-9	53

1400	Molecular targeted therapies in hepatocellular carcinoma. 2008 , 48, 1312-27	801
1399	Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. 2008 , 1784, 193-202	142
1398	Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide. 2008 , 16, 5277-84	14
1397	Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. 2008 , 16, 7543-51	79
1396	Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors. 2008 , 18, 1967-71	40
1395	Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. 2008 , 18, 2793-8	52
1394	High-throughput colorimetric detection of tyrosine kinase inhibitors based on the aggregation of gold nanoparticles. 2008 , 373, 161-3	29
1393	Phospho-proteomic approach to identify new targets of leucine deprivation in muscle cells. 2008 , 381, 148-50	11
1392	Doing more than just the structure-structural genomics in kinase drug discovery. 2008 , 12, 40-5	36
1391	Allosteric modulation of kinases and GPCRs: design principles and structural diversity. 2008 , 12, 269-80	73
1390	Synthesis of novel hymenialdisine analogues using solvent-free and silica gel-promoted ring opening of epoxides. 2008 , 64, 7171-7177	20
1389	Concise syntheses of stereoisomeric hexahydroazepine derivatives related to the protein kinase inhibitor balanol. 2008 , 49, 5498-5501	13
1388	Src family kinases: regulation of their activities, levels and identification of new pathways. 2008 , 1784, 56-65	238
1387	Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. 2008 , 51, 5229-42	108
1386	Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. 2008 , 51, 1214-22	83
1385	An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling. 2008 , 27, 2955-65	44
1384	Activation of tyrosine kinases by mutation of the gatekeeper threonine. 2008 , 15, 1109-18	311
1383	Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries. 2008 , 3, 1350-63	31

1382	Prediction of specificity-determining residues for small-molecule kinase inhibitors. 2008 , 9, 491	17
1381	Protozoan protein tyrosine phosphatases. 2008 , 38, 1279-95	39
1380	Enzyme catalysis on solid surfaces. 2008 , 26, 328-37	85
1379	Protein Ser/Thr phosphatases of parasitic protozoa. 2008 , 161, 81-90	46
1378	Colorimetric enzymatic activity assay based on noncrosslinking aggregation of gold nanoparticles induced by adsorption of substrate peptides. 2008 , 9, 2301-8	57
1377	Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. 2008 , 3, 1409-25	71
1376	Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. 2008 , 51, 7921-32	142
1375	Protein kinase CK2 as a druggable target. 2008 , 4, 889-94	98
1374	Isoform-selective histone deacetylase inhibitors. 2008 , 37, 1402-13	255
1373	Bicyclic 5-6 Systems: Purines. 2008 , 525-597	3
1372	Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors. 2008 , 4, 542-50	7
1371	A Passivity-Based Approach to Stability of Spatially Distributed Systems With a Cyclic Interconnection Structure. 2008 , 53, 75-86	24
1370	Regulation of tissue factor procoagulant activity by post-translational modifications. 2008 , 122, 831-7	23
1369	Drugging the Plasmodium kinome: the benefits of academia-industry synergy. 2008 , 29, 241-9	36
1368	Cytochrome P450 inhibition profile in liver of veal calves administered a combination of 17beta-estradiol, clenbuterol, and dexamethasone for growth-promoting purposes. 2008 , 46, 2849-55	22
1367	Effects of a protein kinase C inhibitor on the initial development of ectopic implants in a syngeneic mouse model of endometriosis. 2008 , 89, 206-11	7
1366	Salicylaldehyde derivatives as new protein kinase CK2 inhibitors. 2008 , 1780, 1412-20	11
1365	Linking the kinome and phosphorylome--a comprehensive review of approaches to find kinase targets. 2008 , 4, 920-33	40

- 1364 Peptide biosensors for the electrochemical measurement of protein kinase activity. **2008**, 80, 9395-401 78
- 1363 Peptides and Peptidomimetics as Cancer Therapy Sensitizing Agents. **2008**, 279-303
- 1362 Proteomics-based strategies in kinase drug discovery. **2007**, 1-28 13
- 1361 p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. **2008**, 10, 314-29 67
- 1360 Recent developments in mass spectrometry-based quantitative phosphoproteomics. **2008**, 86, 137-48 33
- 1359 Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. **2008**, 3, 959-78 16
- 1358 Electrochemical detection of kinase-catalyzed phosphorylation using ferrocene-conjugated ATP. **2008**, 502-4 87
- 1357 Putative allosteric MEK1 and MEK2 inhibitors. **2008**, 18, 603-627 23
- 1356 Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects. **2008**, 51, 6225-9 13
- 1355 Cerium ion-chelated magnetic silica microspheres for enrichment and direct determination of phosphopeptides by matrix-assisted laser desorption ionization mass spectrometry. **2008**, 7, 1767-77 74
- 1354 Enzyme kinetics and binding studies on inhibitors of MEK protein kinase. **2008**, 47, 5017-27 22
- 1353 Quantitative phosphoproteome analysis of lysophosphatidic acid induced chemotaxis applying dual-step (18)O labeling coupled with immobilized metal-ion affinity chromatography. **2008**, 7, 4215-24 16
- 1352 In situ monitoring of bindings between dasatinib and its target protein kinases using magnetic nanoparticles in live cells. **2008**, 130, 16466-7 8
- 1351 Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. **2008**, 51, 1179-88 54
- 1350 NMR screening for lead compounds using tryptophan-mutated proteins. **2008**, 51, 5035-42 11
- 1349 Spheciosterol sulfates, PKCzeta inhibitors from a philippine sponge Spheciospongia sp. **2008**, 71, 1213-7 31
- 1348 Bioactive polybrominated diphenyl ethers from the marine sponge Dysidea sp. **2008**, 71, 262-4 26
- 1347 RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. **2008**, 389, 1273-82 84

1346	Phosphorylation of the human full-length protein kinase Ciota. 2008 , 7, 2928-35	8
1345	Recognition-domain focused chemosensors: versatile and efficient reporters of protein kinase activity. 2008 , 130, 12821-7	80
1344	Targeting the unactivated conformations of protein kinases for small molecule drug discovery. 2008 , 3, 595-605	27
1343	PTEN-deficient cancers depend on PIK3CB. 2008 , 105, 13057-62	427
1342	The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. 2008 , 105, 6386-91	113
1341	Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. 2008 , 283, 15419-30	43
1340	Non-ATP-competitive kinase inhibitors - enhancing selectivity through new inhibition strategies. 2008 , 3, 761-74	13
1339	Recent advances in the development of multi-kinase inhibitors. 2008 , 8, 1312-27	68
1338	The challenge of selecting protein kinase assays for lead discovery optimization. 2008 , 3, 607-621	142
1337	Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. 2008 , 1, 156-60	65
1336	Alternative assay formats to identify diverse inhibitors of protein kinases. 2008 , 3, 819-31	3
1335	Current status of HTRF() technology in kinase assays. 2008 , 3, 1461-74	13
1334	Emr2, a structural homologue of Emr, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/Emr. 2008 , 410, 309-17	24
1333	Personalizing protein-drug interactions. 2008 , 80, 1811-1820	1
1332	. 2008 ,	3
1331	Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs. 2008 , 1, 1-12	13
1330	Development of a HTRF kinase assay for determination of Syk activity. 2008 , 1, 20-6	13
1329	Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure In Vitro (Pharmacology&ADME) In Vivo (Safety) Relationships. 2008 , 23-52	8

1328	Strategies for Discovering Kinase Drugs. 2008 , 119-157	
1327	The cAMP-dependent protein kinase inhibitor H-89 attenuates the bioluminescence signal produced by Renilla Luciferase. 2009 , 4, e5642	21
1326	The emerging complexity of protein ubiquitination. 2009 , 37, 937-53	564
1325	Selectivity of docking sites in MAPK kinases. 2009 , 284, 13165-73	93
1324	Targeting protein serine/threonine phosphatases for drug development. 2009 , 75, 1249-61	142
1323	Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization. 2009 , 106, 20204-9	49
1322	A conserved protonation-dependent switch controls drug binding in the Abl kinase. 2009 , 106, 139-44	216
1321	Phosphate-Affinity Gel Electrophoresis Using a Phos-Tag Molecule for Phosphoproteome Study. 2009 , 6, 104-121	16
1320	Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. 2009 , 8, 2796-808	165
1319	Development of an insect-cell-based assay for detection of kinase inhibition using NF-kappaB-inducing kinase as a paradigm. 2009 , 419, 65-73	6
1318	Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. 2009 , 16, 1964-77	51
1317	Protein phosphorylation by semisynthesis: from paper to practice. 2009 , 462, 1-24	21
1316	Exploring the roles of protein kinases using chemical genetics. 2009 , 1, 1233-41	3
1315	A survey of the population genetic variation in the human kinome. 2009 , 54, 488-92	1
1314	Identification and specific localization of tyrosine-phosphorylated proteins in Trypanosoma brucei. 2009 , 8, 617-26	33
1313	Genome to kinome: species-specific peptide arrays for kinome analysis. 2009 , 2, pl1	68
1312	Correction for interference by test samples in high-throughput assays. 2009 , 14, 1008-16	49
1311	Functional analysis of protein kinase CK2 of the human malaria parasite Plasmodium falciparum. 2009 , 8, 388-97	35

1310	Structure-based design of molecular cancer therapeutics. 2009 , 27, 315-28	57
1309	Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. 2009 , 14, 291-7	113
1308	Revealing promiscuous drug-target interactions by chemical proteomics. 2009 , 14, 1021-9	106
1307	Structural biology contributions to tyrosine kinase drug discovery. 2009 , 21, 280-7	46
1306	B cell receptor-induced growth arrest and apoptosis in WEHI-231 immature B lymphoma cells involve cyclic AMP and Epac proteins. 2009 , 21, 609-21	19
1305	MALDI-TOF mass-spectrometry-based versatile method for the characterization of protein kinases. 2009 , 15, 1413-21	17
1304	Exploring kinase cosubstrate promiscuity: monitoring kinase activity through dansylation. 2009 , 10, 234-7	30
1303	Off-target decoding of a multitarget kinase inhibitor by chemical proteomics. 2009 , 10, 1163-74	14
1302	Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays. 2009 , 10, 2042-51	32
1301	Dynamic visualization of signal transduction in living cells: from second messengers to kinases. 2009 , 61, 902-8	25
1300	Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease. 2009 , 70, 125-144	24
1299	Two-dimensional phosphate-affinity gel electrophoresis for the analysis of phosphoprotein isotypes. 2009 , 30, 550-9	42
1298	Platinum-Catalyzed Intramolecular Cyclizations of Alkynes: Efficient Synthesis of Pyrroloazepinone Derivatives. 2009 , 121, 7348-7352	11
1297	Platinum-catalyzed intramolecular cyclizations of alkynes: efficient synthesis of pyrroloazepinone derivatives. 2009 , 48, 7212-6	54
1296	A methods-based biotechnology course for undergraduates. 2009 , 37, 227-31	2
1295	Synthesis of C-linked immobilized analogs of aloisine A by click chemistry. 2009 , 50, 741-744	6
1294	A diversity oriented, microwave assisted synthesis of N-substituted 2-hydro-4-amino-pyrido[2,3-d]pyrimidin-7(8H)-ones. 2009 , 13, 39-45	5
1293	Molecular imaging of phosphorylation events for drug development. 2009 , 11, 144-58	24

1292	Measuring and interpreting the selectivity of protein kinase inhibitors. 2009 , 2, 131-51	119
1291	Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. 2009 , 66, 1868-89	75
1290	A pooling-based genome-wide analysis identifies new potential candidate genes for atopy in the European Community Respiratory Health Survey (ECRHS). 2009 , 10, 128	41
1289	Threonine phosphorylation prevents promoter DNA binding of the Group B Streptococcus response regulator CovR. 2009 , 71, 1477-95	69
1288	Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. 2009 , 62, 17-26	133
1287	Attacking cancer at its foundation. 2009 , 15, 1153-7	19
1286	Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. 2009 , 4, 1513-21	279
1285	Targeting cancer with small molecule kinase inhibitors. 2009 , 9, 28-39	1963
1284	Targeting innate immunity protein kinase signalling in inflammation. <i>Nature Reviews Drug Discovery</i> , 2009 , 8, 480-99	64.1 255
1283	On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. 2009 , 74, 16-24	62
1282	Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. 2009 , 108, 147-57	14
1281	Electrochemical detection of protein tyrosine kinase-catalysed phosphorylation using gold nanoparticles. 2009 , 24, 1484-9	56
1280	Automated metal-free multiple-column nanoLC for improved phosphopeptide analysis sensitivity and throughput. 2009 , 877, 663-70	29
1279	Microarray-based Raman spectroscopic assay for kinase inhibition by gold nanoparticle probes. 2009 , 24, 3335-9	43
1278	Identification of potential cellular targets of aloisine A by affinity chromatography. 2009 , 17, 5572-82	5
1277	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. 2009 , 17, 6914-25	44
1276	Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. 2009 , 17, 7281-9	50
1275	N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping. 2009 , 19, 1349-56	23

1274	4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors. 2009 , 19, 5071-4	5
1273	Small kinase assay panels can provide a measure of selectivity. 2009 , 19, 5861-3	18
1272	Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases. 2009 , 19, 6098-101	11
1271	Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). 2009 , 19, 6700-5	55
1270	N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases. 2009 , 19, 6836-9	22
1269	Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates. 2009 , 384, 56-67	11
1268	High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK. 2009 , 385, 85-93	49
1267	A Phos-tag-based fluorescence resonance energy transfer system for the analysis of the dephosphorylation of phosphopeptides. 2009 , 388, 235-41	16
1266	Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology. 2009 , 391, 31-8	27
1265	A fluorescence resonance energy transfer-based binding assay for characterizing kinase inhibitors: important role for C-terminal biotin tagging of the kinase. 2009 , 395, 256-62	5
1264	The chemical biology of protein phosphorylation. 2009 , 78, 797-825	178
1263	Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. 2009 , 64, 1-4	90
1262	Protein kinase inhibitors: contributions from structure to clinical compounds. 2009 , 42, 1-40	196
1261	Titanium dioxide coated MALDI plate for on target analysis of phosphopeptides. 2009 , 8, 1932-42	67
1260	Solid-phase synthesis of 4(5),1',5'-trisubstituted 2,4'-biimidazoles. 2009 , 74, 9446-51	4
1259	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp. 2009 , 72, 1520-3	8
1258	A scalable synthesis of the IP7 isomer, 5-PP-Ins(1,2,3,4,6)P5. 2009 , 11, 1551-4	25
1257	Impact of drug discovery on stem cell biology. 2009 , 383, 275-9	7

1256	Halogen bonding--a novel interaction for rational drug design?. 2009 , 52, 2854-62	485
1255	Variolins and related alkaloids. 2009 , 109, 3080-98	194
1254	Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. 2009 , 81, 4493-501	226
1253	3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds. 2009 , 52, 4683-93	63
1252	Understanding the regulation of Group B Streptococcal virulence factors. 2009 , 4, 201-21	128
1251	Identification of serine/threonine kinase substrates in the human pathogen group B streptococcus. 2009 , 8, 2563-74	34
1250	Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations. 2009 , 6, 605-18	31
1249	Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. 2009 , 4, e8470	37
1248	Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. 2009 , 52, 308-21	31
1247	Trk kinase inhibitors as new treatments for cancer and pain. 2009 , 19, 305-19	88
1246	Affinity classification of kinase inhibitors by mass spectrometric methods and validation using standard IC(50) measurements. 2009 , 81, 408-19	26
1245	Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. 2009 , 52, 3881-91	39
1244	ADP-Glo: A Bioluminescent and homogeneous ADP monitoring assay for kinases. 2009 , 7, 560-72	140
1243	Evaluation of an antibody-free ADP detection assay: ADP-Glo. 2009 , 7, 598-605	15
1242	A DNA-based electrochemical strategy for label-free monitoring the activity and inhibition of protein kinase. 2009 , 6946-8	64
1241	Comparison of the luminescent ADP-Glo assay to a standard radiometric assay for measurement of protein kinase activity. 2009 , 7, 615-22	10
1240	Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay. 2009 , 7, 56-67	39
1239	Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors. 2009 , 1, 1453-66	6

- 1238 Identification of peptide substrate and small molecule inhibitors of testis-specific serine/threonine kinase1 (TSSK1) by the developed assays. **2009**, 52, 4419-28 11
- 1237 Synthesis of new aza-analogs of staurosporine, K-252a and rebeccamycin by nucleophilic opening of C2-symmetric bis-aziridines. **2009**, 7, 706-16 15
- 1236 Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry. **2009**, 7, 5129-36 34
- 1235 Innovative approaches to the therapy of fibrosis. **2009**, 21, 649-55 17
- 1234 Functional isolation of staurosporine binding protein kinases using CCMS technology. **2009**, 6, iii-iv
- 1233 Side Effects of Molecularly Targeted Drugs and Their Molecular Mechanisms. **2009**, 55, 338-346
- 1232 Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents. **2010**, 6, 306-12 31
- 1231 Structural Genomics, Its Application in Chemistry, Biology, and Drug Discovery. **2010**, 569-600
- 1230 Receptor Targets in Drug Discovery. **2010**, 499-548
- 1229 Halogenated indole alkaloids from marine invertebrates. **2010**, 8, 1526-49 64
- 1228 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia. **2010**, 493-506 1
- 1227 Noble Metal Nanoparticles as Colorimetric Probes for Biological Analysis. **2010**, 183-214
- 1226 Functional Assays for Protein Kinases. **2010**, 181-212
- 1225 Selectively nonselective kinase inhibition: striking the right balance. **2010**, 53, 1413-37 247
- 1224 Mitochondrial tyrosine phosphoproteome: new insights from an up-to-date analysis. **2010**, 36, 437-50 11
- 1223 Development of an online p38 β mitogen-activated protein kinase binding assay and integration of LC-HR-MS. **2010**, 398, 1771-80 30
- 1222 Synthesis of non glycosidic nucleobase-sugar mimetics. **2010**, 13, 1284-1300 5
- 1221 Hepatoma-targeted gene delivery using a tumor cell-specific gene regulation system combined with a human liver cell-specific bionanocapsule. **2010**, 6, 583-9 14

1220	Novel regulators of stem cell fates identified by a multivariate phenotype screen of small compounds on human embryonic stem cell colonies. 2010 , 5, 104-19	44
1219	The kinome of <i>Phytophthora infestans</i> reveals oomycete-specific innovations and links to other taxonomic groups. 2010 , 11, 700	28
1218	Strategies for the identification of kinase substrates using analog-sensitive kinases. 2010 , 89, 184-93	22
1217	HIV-1 Tat-peptide inhibits protein kinase C and protein kinase A through substrate competition. 2010 , 40, 404-11	13
1216	In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. 2010 , 18, 244-57	203
1215	Src redox regulation: again in the front line. 2010 , 49, 516-27	93
1214	RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. 2010 , 118, 220-7	51
1213	Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor. 2010 , 5, 255-67	26
1212	Molecular approaches to examine the phosphorylation state of the C type natriuretic peptide receptor. 2010 , 110, 985-94	10
1211	Bacterial protein kinase inhibitors. 2010 , 71, n/a-n/a	6
1210	A CE-based assay for human protein kinase CK2 activity measurement and inhibitor screening. 2010 , 31, 634-40	46
1209	RAF kinase inhibitors in cancer treatment: like a bull in a China shop?. 2010 , 11, 1645-8	1
1208	Peptide reporters of kinase activity in whole cell lysates. 2010 , 94, 475-86	32
1207	Substrate screening of protein kinases: detection methods and combinatorial peptide libraries. 2010 , 94, 753-62	24
1206	Insights into protein kinase regulation and inhibition by large scale structural comparison. 2010 , 1804, 429-32	40
1205	Bisubstrate fluorescent probes and biosensors in binding assays for HTS of protein kinase inhibitors. 2010 , 1804, 541-6	12
1204	The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, (57)Fe Mössbauer), theoretical, and biological activity studies. 2010 , 104, 405-17	16
1203	A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors. 2010 , 28, 683-94	26

1202	A gene-delivery system specific for hepatoma cells and an intracellular kinase signal based on human liver-specific bionanocapsules and signal-responsive artificial polymer. 2010 , 396, 174-8	6
1201	Aza-beta(3)-amino acid containing peptidomimetics as cAMP-dependent protein kinase substrates. 2010 , 38, 229-33	7
1200	Synthesis of pyrroloazepinones: platinum- and gold-catalyzed cyclization reactions of alkynes. 2010 , 66, 3341-3352	36
1199	A fluorescence lifetime-based assay for serine and threonine kinases that is suitable for high-throughput screening. 2010 , 402, 54-64	10
1198	A quantitative mass spectrometry-based approach for identifying protein kinase clients and quantifying kinase activity. 2010 , 402, 69-76	24
1197	Real-time fluorogenic kinase assay using protein as substrate. 2010 , 406, 14-8	
1196	Regulation of cell proliferation and survival: convergence of protein kinases and caspases. 2010 , 1804, 505-10	56
1195	Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. 2010 , 1804, 454-62	51
1194	Affinity reagents that target a specific inactive form of protein kinases. 2010 , 17, 195-206	31
1193	Switchable "On-Off" electrochemical technique for detection of phosphorylation. 2010 , 26, 638-42	31
1192	Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. 2010 , 20, 4045-9	22
1191	An enriched structural kinase database to enable kinome-wide structure-based analyses and drug discovery. 2010 , 19, 763-74	39
1190	Calculating pKa values in the cAMP-dependent protein kinase: the effect of conformational change and ligand binding. 2010 , 19, 2485-97	4
1189	Unrestrictive identification of non-phosphorylation PTMs in yeast kinases by MS and PTMap. 2010 , 10, 896-903	6
1188	QIKS--Quantitative identification of kinase substrates. 2010 , 10, 2015-25	25
1187	Engineering nanocomposite materials for cancer therapy. 2010 , 6, 2336-57	205
1186	The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. 2010 , 159, 265-84	117
1185	. 2010 ,	25

1184	. 2010,	15
1183	Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. 2010, 15, 8260-78	48
1182	Classification of protein kinases on the basis of both kinase and non-kinase regions. 2010, 5, e12460	21
1181	Protein Phosphatase 1 as a Potential Mediator of Aluminum Neurotoxicity. 2010, 173-179	
1180	Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. 2010, 3, rs4	229
1179	Drugging the PI3 kinome: from chemical tools to drugs in the clinic. 2010, 70, 2146-57	226
1178	Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors. 2010, 5, 277-90	17
1177	Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen. 2010, 8, 47-62	1
1176	Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis. 2010, 207, 2507-19	51
1175	Quantitative measurement of in vivo phosphorylation states of Cdk5 activator p35 by Phos-tag SDS-PAGE. 2010, 9, 1133-43	50
1174	Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. 2010, 26, 198-204	104
1173	Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors. 2010, 17, 234-53	15
1172	Proteochemometric recognition of stable kinase inhibition complexes using topological autocorrelation and support vector machines. 2010, 50, 1179-88	30
1171	Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. 2010, 5, 563-76	87
1170	Antimalarials. 2010, 601-710	3
1169	Screening kinase inhibitors with a microarray-based fluorescent and resonance light scattering assay. 2010, 82, 3067-72	43
1168	Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS. 2010, 21, 1917-24	5
1167	Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. 2010, 9, 3218-24	18

1166	Development of stable phosphohistidine analogues. 2010 , 132, 14327-9	114
1165	Scaffold-based design of kinase inhibitors for cancer therapy. 2010 , 20, 79-86	14
1164	Small-molecule FRET probes for protein kinase activity monitoring in living cells. 2010 , 397, 750-5	19
1163	Will the ubiquitin system furnish as many drug targets as protein kinases?. 2010 , 143, 686-93	229
1162	Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking. 2010 , 11, 3705-24	21
1161	The use of click chemistry in the emerging field of catalomics. 2010 , 8, 1749-62	51
1160	Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO ₂ nanoparticle deposited capillary column. 2010 , 135, 2858-63	11
1159	Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS). 2010 , 9, 806-17	53
1158	Assessment of CK2 constitutive activity in cancer cells. 2010 , 484, 495-514	34
1157	Protein kinase-actuated resonance energy transfer in quantum dot-peptide conjugates. 2010 , 4, 4915-9	91
1156	Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. 2010 , 5, 121-38	48
1155	Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. 2010 , 13, 691-719	141
1154	A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. 2010 , 132, 11727-35	54
1153	Small molecule probes that target Abl kinase. 2010 , 46, 1118-20	33
1152	Screening kinase inhibitors with microarray-based Raman spectroscopic assay. 2011 , 3, 1003	6
1151	Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches. 2011 , 7, 2368-74	32
1150	Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. 2011 , 7, 447-56	12
1149	Optimization of immunoaffinity enrichment and detection: toward a comprehensive characterization of the phosphotyrosine proteome of K562 cells by liquid chromatography-mass spectrometry. 2011 , 136, 1971-8	16

1148	Insights into the phosphoryl transfer mechanism of cyclin-dependent protein kinases from ab initio QM/MM free-energy studies. 2011 , 115, 13713-22	30
1147	VX680 binding in Aurora A: π -interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. 2011 , 115, 3895-904	10
1146	De novo design of quinazoline derivatives as CDK2 inhibitors: 3D-QSAR, molecular fragment replacement and Volsurf predictions. 2011 , 37, 824-836	2
1145	Single-step kinase inhibitor screening using a peptide-modified gold nanoparticle platform. 2011 , 47, 2249-51	34
1144	Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library. 2011 , 2, 545	45
1143	ATP-binding site of bacterial enzymes as a target for antibacterial drug design. 2011 , 54, 915-29	59
1142	A Phos-tag-based fluorescence resonance energy transfer system for the analysis of the kinase reaction of a substrate peptide. 2011 , 3, 1303	14
1141	Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe. 2011 , 47, 11306-8	58
1140	Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets. 2011 , 2, 662-6	24
1139	Dissecting phosphorylation networks: lessons learned from yeast. 2011 , 8, 775-86	15
1138	A QM/MM study of the phosphoryl transfer to the Kemptide substrate catalyzed by protein kinase A. The effect of the phosphorylation state of the protein on the mechanism. 2011 , 13, 530-9	23
1137	Cyclin-dependent kinases: bridging their structure and function through computations. 2011 , 3, 1551-9	16
1136	Post-Translationally Modified Proteins: Glycosylation, Phosphorylation, and Disulfide Bond Formation. 2011 , 321-369	
1135	Chapter 3: The Learning and Evolution of Medicinal Chemistry against Kinase Targets. 2011 , 79-95	1
1134	Detection of lysozyme magnetic relaxation switches based on aptamer-functionalized superparamagnetic nanoparticles. 2011 , 83, 7795-9	76
1133	Label-free fluorescent detection of protein kinase activity based on the aggregation behavior of unmodified quantum dots. 2011 , 83, 52-9	119
1132	Protein-induced long lifetime luminescence of nonmetal probes. 2011 , 6, 1052-62	35
1131	Post-translational Modifications in Apicomplexan Parasites. 2011 , 93-120	1

1130	A quantitative literature-curated gold standard for kinase-substrate pairs. 2011 , 12, R39	44
1129	[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors. 2011 , 2, 65-72	37
1128	Cloning, expression analysis and promoter structure of TBK1 (TANK-binding kinase 1) in Atlantic cod (<i>Gadus morhua</i> L.). 2011 , 30, 1055-63	22
1127	Synthesis and biological evaluation of 2,3-bis(het)aryl-4-azaindole derivatives as protein kinase inhibitors. 2011 , 2, 899	26
1126	Structure and substrate recognition of the <i>Staphylococcus aureus</i> protein tyrosine phosphatase PtpA. 2011 , 413, 24-31	19
1125	Signal transduction in <i>Trypanosoma cruzi</i> . 2011 , 75, 325-44	13
1124	Groebke multicomponent reaction and subsequent nucleophilic aromatic substitution for a convenient synthesis of 3,8-diaminoimidazo[1,2-a]pyrazines as potential kinase inhibitors. 2011 , 9, 4144-9	15
1123	Elucidating substrate and inhibitor binding sites on the surface of GSK-3 β and the refinement of a competitive inhibitor. 2011 , 408, 366-78	21
1122	Management of Heart Failure Patients with Malignancy. 2011 , 845-853	
1121	Molecular Modeling study of Protein Kinase PKnB from <i>Mycobacterium Tuberculosis</i> with derivatives of 1, 3, 4- Thiadiazoles. 2011 ,	2
1120	Cancer and Treatment with Seeds of Chinese Fan Palm (<i>Livistona chinensis</i> R. Brown). 2011 , 325-331	
1119	A transient increase in total head phosphotyrosine levels is observed upon the emergence of <i>Aedes aegypti</i> from the pupal stage. 2011 , 106, 546-52	5
1118	Bridging quantum mechanics and structure-based drug design. 2011 , 16, 1619-33	50
1117	Biosensors Involved in Drug Discovery. 2011 , 61-94	
1116	Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors. 2011 , 6, e22644	20
1115	Protein kinases as drug targets. 2011 , 11, 1304	1
1114	Bacterial eukaryotic type serine-threonine protein kinases: from structural biology to targeted anti-infective drug design. 2011 , 11, 1352-69	28
1113	Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase. 2011 , 14, 669-87	10

1112	Biology of transforming growth factor- β signaling. 2011 , 12, 2099-107	37
1111	Chemical and pharmacological significance of natural guanidines from marine invertebrates. 2011 , 11, 225-46	21
1110	Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. 2011 , 25, 248-57	45
1109	Roles of the SH2 and SH3 domains in the regulation of neuronal Src kinase functions. 2011 , 278, 643-53	10
1108	Melatonin triggers PKA activation in the rodent malaria parasite <i>Plasmodium chabaudi</i> . 2011 , 50, 64-70	30
1107	Enhanced kinase sensing by radio-phosphorylation and oriented immobilization of a GBP-linked kinase substrate on a gold surface. 2011 , 160, 632-636	1
1106	Drug discovery and the human kinome: recent trends. 2011 , 130, 144-56	61
1105	Substrate profiling of IGF-1R and InsR: identification of a potent pentamer substrate. 2011 , 21, 7030-3	1
1104	A general framework for inhibitor resistance in protein kinases. 2011 , 18, 966-75	41
1103	Allosteric regulation of protein kinase PKC β by the N-terminal C1 domain and small compounds to the PIF-pocket. 2011 , 18, 1463-73	48
1102	Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. 2011 , 392, 837-47	57
1101	The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. 2011 , 80, 769-95	260
1100	The Synthesis of Some Derivatives Based on the 4-Benzyl-1H-pyrazole-3,5-diamine Core. 2011 , 83, 371	3
1099	Convergent assembly of structurally diverse quinazolines. 2011 , 9, 351-7	6
1098	Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. 2011 , 54, 4042-56	60
1097	Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype. 2011 , 25, 873-83	2
1096	Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays. 2011 , 356, 83-90	5
1095	Helianthin induces antiproliferative effect on human glioblastoma cells in vitro. 2011 , 102, 9-18	5

1094	The NMDA receptor NR1 subunit is critically involved in the regulation of NMDA receptor activity by C-terminal Src kinase (Csk). 2011 , 36, 319-26	3
1093	Structural (X-ray), spectral (FT-IR and Raman) and quantum chemical investigations of a series of 6-benzylaminopurine derivatives. 2011 , 994, 350-359	8
1092	Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin. 2011 , 19, 3569-78	13
1091	Serine/threonine protein phosphatases in DNA damage response. 2011 , 56, 3122	6
1090	Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma. 2011 , 4, 62	33
1089	Major prospects for exploring canine vector borne diseases and novel intervention methods using 'omic technologies. 2011 , 4, 53	2
1088	Structure of human dual-specificity phosphatase 27 at 2.38 Å resolution. 2011 , 67, 471-9	16
1087	Quantitative chemical proteomics in small-scale culture of phorbol ester stimulated basal breast cancer cells. 2011 , 11, 2683-92	10
1086	Peptide arrays for kinome analysis: new opportunities and remaining challenges. 2011 , 11, 4595-609	70
1085	Biology of Aurora A kinase: implications in cancer manifestation and therapy. 2011 , 31, 757-93	66
1084	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. 2011 , 31, 924-54	98
1083	Identification of Inhibitors of the Tyrosine Kinase c-Met by Structure-Based Virtual Screening. 2011 , 30, 145-50	1
1082	Synthesis and bioactivity of carbohydrate derivatives of indigo, its isomers and heteroanalogues. 2011 , 6, 25-37	21
1081	Discovery of 4-benzylamino-substituted β -carboline as a novel class of receptor tyrosine kinase inhibitors. 2011 , 6, 63-72	11
1080	Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. 2011 , 26, 1883-90	51
1079	NMR spectroscopic investigations of the activated p38 mitogen-activated protein kinase. 2011 , 12, 2599-607	13
1078	In situ kinase profiling reveals functionally relevant properties of native kinases. 2011 , 18, 699-710	249
1077	High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. 2011 , 18, 868-79	88

1076	Protein kinase affinity reagents based on a 5-aminoindazole scaffold. 2011 , 21, 550-4	5
1075	Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. 2011 , 21, 1342-6	80
1074	Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. 2011 , 21, 2106-12	52
1073	Use of fluorescence lifetime technology to provide efficient protection from false hits in screening applications. 2011 , 409, 89-97	10
1072	Antibody-free peptide substrate screening of serine/threonine kinase (protein kinase A) with a biotinylated detection probe. 2011 , 413, 30-5	3
1071	Systematic screening of protein modifications in four kinases using affinity enrichment and mass spectrometry analysis with unrestrictive sequence alignment. 2011 , 691, 62-7	
1070	Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. 2011 , 46, 2185-92	51
1069	Electrochemical strategy for detection of phosphorylation based on enzyme-linked electrocatalysis. 2011 , 656, 274-278	32
1068	Pani. 2011 ,	4
1067	Role of the non-receptor tyrosine kinase fes in cancer. 2011 , 18, 2913-20	10
1066	Fluorescence lifetime assays: current advances and applications in drug discovery. 2011 , 6, 663-70	10
1065	Outlook of the Antiviral Drug Era, Now More Than 50 Years after Description of the First Antiviral Drug. 2011 , 1-28	
1064	A fluorescence lifetime-based assay for abelson kinase. 2011 , 16, 65-72	12
1063	Serine/threonine phosphatase Stp1 mediates post-transcriptional regulation of hemolysin, autolysis, and virulence of group B Streptococcus. 2011 , 286, 44197-44210	32
1062	Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1. 2011 , 186, 7127-35	38
1061	Dynamically committed, uncommitted, and quenched states encoded in protein kinase A revealed by NMR spectroscopy. 2011 , 108, 6969-74	117
1060	Strategies to generate biological reagents for kinase drug discovery. 2011 , 6, 1215-25	1
1059	Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. 2011 , 3, 29-43	42

1058	Regulatory roles of protein kinases in cytomegalovirus replication. 2011 , 80, 69-101	55
1057	Deciphering the Arginine-binding preferences at the substrate-binding groove of Ser/Thr kinases by computational surface mapping. 2011 , 7, e1002288	11
1056	Proteins with complex architecture as potential targets for drug design: a case study of <i>Mycobacterium tuberculosis</i> . 2011 , 7, e1002118	17
1055	High throughput screens yield small molecule inhibitors of <i>Leishmania</i> CRK3:CYC6 cyclin-dependent kinase. 2011 , 5, e1033	26
1054	Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. 2012 , 33, 799-803	19
1053	Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung. 2012 , 5, 1291-331	24
1052	Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. 2012 , 151, 47-55	15
1051	Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. 2012 , 9, 59-70	5
1050	Malaria, anti malarial drugs and the role of melatonin. 2012 , 12, 371-9	4
1049	The physiological relevance of protein phosphatase 1 and its interacting proteins to health and disease. 2010 , 17, 3996-4017	43
1048	Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. 2012 , 153, 1806-16	38
1047	Targeting protein kinases in the malaria parasite: update of an antimalarial drug target. 2012 , 12, 456-72	36
1046	[Cell cycle and molecular targets: CDK inhibition]. 2012 , 99, 163-71	4
1045	Molecular dynamics of protein kinase-inhibitor complexes: a valid structural information. 2012 , 18, 2946-63	19
1044	Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. 2012 , 41, 496-8	4
1043	Mechanisms of Drug Metabolism. 2012 , 1	
1042	Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome. 2012 , 52, 3107-15	5
1041	Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. 2012 , 58, 171-83	40

1040	ERK1/2 MAP kinases: structure, function, and regulation. 2012 , 66, 105-43	939
1039	Proteome-wide identification of staurosporine-binding kinases using capture compound mass spectrometry. 2012 , 795, 135-47	1
1038	βSynuclein phosphorylation as a therapeutic target in Parkinson's disease. 2012 , 23, 191-8	41
1037	Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. 2012 , 14, R22	59
1036	Directed modulation of protein kinase C isozyme selectivity with bisubstrate-based inhibitors. 2012 , 7, 2113-21	7
1035	Computation of relative binding free energy for an inhibitor and its analogs binding with Erk kinase using thermodynamic integration MD simulation. 2012 , 26, 1159-69	19
1034	Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. 2012 , 19, 1152-63	52
1033	The <i>Entamoeba histolytica</i> serum-inducible transmembrane kinase EhTMKB1-9 is involved in intestinal amebiasis. 2012 , 2, 243-248	13
1032	Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry. 2012 , 76 Spec No., 36-42	16
1031	Discovery and structural insight of a highly selective protein kinase inhibitor hit through click chemistry. 2012 , 48, 2788-90	6
1030	Electrochemical investigations into Tau protein phosphorylations. 2012 , 137, 2042-6	33
1029	Structural basis for nucleotide binding and reaction catalysis in mevalonate diphosphate decarboxylase. 2012 , 51, 5611-21	21
1028	Kinase-Catalyzed Biotinylation. 2012 , 4, 83-100	4
1027	Electrochemical strategy for sensing protein phosphorylation. 2012 , 23, 141-5	70
1026	Detection of low-abundance protein phosphorylation by selective 18O labeling and mass spectrometry. 2012 , 84, 7384-92	4
1025	Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. 2012 , 7, 487-95	22
1024	Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. 2012 , 134, 3001-14	174
1023	Chasing phosphohistidine, an elusive sibling in the phosphoamino acid family. 2012 , 7, 44-51	93

1022	Ectodomain structures of Eph receptors. 2012 , 23, 35-42	48
1021	A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. 2012 , 166, 858-76	76
1020	Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. 2012 , 7, 1830-9	135
1019	Cell signaling, post-translational protein modifications and NMR spectroscopy. 2012 , 54, 217-36	129
1018	Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations. 2012 , 52, 2992-3000	6
1017	Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. 2012 , 9, 3062-78	15
1016	Label-free electrochemical impedance detection of kinase and phosphatase activities using carbon nanofiber nanoelectrode arrays. 2012 , 744, 45-53	21
1015	The kinomes of apicomplexan parasites. 2012 , 14, 796-810	48
1014	TF--a novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP. 2012 , 1820, 970-7	24
1013	Probing the kinome in real time with fluorescent peptides. 2012 , 41, 1652-64	72
1012	Bioactive Marine Prenylated Quinones/Quinolins. 2012 , 163-218	12
1011	Comprehensive phosphoproteome analysis of INS-1 pancreatic β cells using various digestion strategies coupled with liquid chromatography-tandem mass spectrometry. 2012 , 11, 2206-23	21
1010	Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP. 2012 , 795, 119-34	8
1009	Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. 2012 , 55, 1189-204	48
1008	Targeting cancer with small-molecular-weight kinase inhibitors. 2012 , 795, 1-34	98
1007	Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP. 2012 , 68, 1434-9	10
1006	The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: a proof-of-concept study. 2012 , 57, 1-9	13
1005	Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases. 2012 , 68, 9713-9728	13

1004	Targeting the inactive conformation of protein kinases: computational screening based on ligand conformation. 2012 , 3, 434-440	9
1003	Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1. 2012 , 928, 133-41	3
1002	Affinity purification of protein kinases that adopt a specific inactive conformation. 2012 , 928, 143-51	1
1001	An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents. 2012 , 928, 175-84	1
1000	Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen. 2012 , 55, 1526-37	21
999	Versatile strategy for biochemical, electrochemical and immunoarray detection of protein phosphorylations. 2012 , 134, 17036-45	65
998	Roles of Polo-like kinase 3 in suppressing tumor angiogenesis. 2012 , 1, 5	17
997	Allostery and binding cooperativity of the catalytic subunit of protein kinase A by NMR spectroscopy and molecular dynamics simulations. 2012 , 87, 363-89	33
996	A chemical genetic approach for covalent inhibition of analogue-sensitive aurora kinase. 2012 , 7, 723-31	18
995	Analysis of signalling pathways by western blotting and immunoprecipitation. 2012 , 816, 223-32	2
994	N-N bond-forming cyclization for the one-pot synthesis of N-aryl[3,4-d]pyrazolopyrimidines. 2012 , 14, 3546-9	19
993	Review: Recent Developments in Enzyme-Based Biosensors for Biomedical Analysis. 2012 , 45, 168-186	128
992	Kinase Inhibitors. 2012 ,	2
991	PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. 2012 , 7, e33752	55
990	Cdk5: An Emerging Kinase in Pain Signaling. 2013 , 2013,	6
989	Dephosphorylation proves detrimental to GABAergic inhibition. 2012 , 12, 22-3	
988	Allosteric regulation of PKC—understanding multistep phosphorylation and priming by ligands in AGC kinases. 2012 , 80, 269-80	10
987	Halogen bonding for rational drug design and new drug discovery. 2012 , 7, 375-83	202

986	Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index. 2012 , 11, 3637-49	5
985	Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. 2012 , 8, 366-74	53
984	The steroid hormone 20-hydroxyecdysone upregulated the protein phosphatase 6 for the programmed cell death in the insect midgut. 2012 , 43, 963-71	7
983	Electrochemical screening of the indole/quinolone derivatives as potential protein kinase CK2 inhibitors. 2012 , 421, 617-21	11
982	Time-gated luminescence assay using nonmetal probes for determination of protein kinase activity-based disease markers. 2012 , 422, 79-88	18
981	The regulation of N-methyl-D-aspartate receptors by Src kinase. 2012 , 279, 20-8	47
980	Optimizing targeted cancer therapy: towards clinical application of systems biology approaches. 2012 , 82, 171-86	19
979	Design, synthesis and biological evaluation of novel (E)- β -benzylsulfonyl chalcone derivatives as potential BRAF inhibitors. 2012 , 50, 288-95	27
978	Highly sensitive protein kinase activity assay based on electrochemiluminescence nanoprobe. 2012 , 31, 299-304	33
977	Key strongylid nematodes of animals - Impact of next-generation transcriptomics on systems biology and biotechnology. 2012 , 30, 469-88	34
976	IB kinase regulation of the TPL-2/ERK MAPK pathway. 2012 , 246, 168-82	99
975	Utilization of DmbNHNH ₂ in the synthesis of amino-substituted 4-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenols. 2012 , 68, 3996-4002	10
974	Highly efficient synthesis of 5,6-disubstituted-5H-pyrrolo[2,3-b]pyrazine-2,3-dicarbonitriles through a one-pot palladium-catalyzed coupling reaction/cyclization in water. 2012 , 53, 3126-3130	18
973	Differential effects on cell motility, embryonic stem cell self-renewal and senescence by diverse Src kinase family inhibitors. 2012 , 318, 336-49	7
972	A physicochemical descriptor-based scoring scheme for effective and rapid filtering of kinase-like chemical space. 2012 , 4, 4	14
971	Current chemical biology tools for studying protein phosphorylation and dephosphorylation. 2012 , 18, 28-39	36
970	Regulation of voltage-gated sodium current by endogenous Src family kinases in cochlear spiral ganglion neurons in culture. 2012 , 463, 571-84	6
969	Applications of Mass Spectrometry in Proteomics. 2013 , 66, 721	24

968	Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. 2013 , 34, 3519-28	29
967	Global proteome analysis of the NCI-60 cell line panel. 2013 , 4, 609-20	225
966	Protein tyrosine phosphatases: structure, function, and implication in human disease. 2013 , 1053, 179-221	63
965	Decoding the <i>Ascaris suum</i> Genome using Massively Parallel Sequencing and Advanced Bioinformatic Methods □ Unprecedented Prospects for Fundamental and Applied Research. 2013 , 287-314	
964	Synthesis and aminomethylation of 7-hydroxy-5-methoxyisoflavones. 2013 , 49, 235-241	10
963	High-throughput screening for protein tyrosine phosphatase activity modulators. 2013 , 1053, 223-40	6
962	Microtubule affinity-regulating kinase 4: structure, function, and regulation. 2013 , 67, 485-99	67
961	Neuroprotective effects of quercetin in chemical hypoxia: in silico evaluation of the hypothesis exploring PKC inhibition-mediated pharmacotherapy. 2013 , 22, 4836-4841	2
960	Pharmacophore modeling, 3D-QSAR, and molecular docking study on naphthyridine derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1. 2013 , 22, 3812-3822	2
959	Nonfitting protein-ligand interaction scoring function based on first-principles theoretical chemistry methods: development and application on kinase inhibitors. 2013 , 34, 1636-46	32
958	Current technologies to identify protein kinase substrates in high throughput. 2013 , 8, 216-227	10
957	Cyclopamine and jervine induce COX-2 overexpression in human erythroleukemia cells but only cyclopamine has a pro-apoptotic effect. 2013 , 319, 1043-53	18
956	Fluorescent detection of protein kinase based on zirconium ions-immobilized magnetic nanoparticles. 2013 , 780, 89-94	28
955	Bioactive iridium and rhodium complexes as therapeutic agents. 2013 , 257, 1764-1776	224
954	The dynamics of signaling as a pharmacological target. 2013 , 155, 448-61	106
953	Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. 2013 , 65, 670-709	187
952	Characterization of a chemical affinity probe targeting Akt kinases. 2013 , 12, 3792-800	24
951	Synthesis and anticancer activities of 5,6,7-trimethoxy-N-phenyl(ethyl)-4-aminoquinazoline derivatives. 2013 , 66, 335-44	18

950	Synthesis of Aminomethyl Derivatives of Chrysin. 2013 , 49, 841-844	6
949	Phosphatomes of Unicellular Eukaryotic Parasites. 2013 , 37-60	
948	K-Map: connecting kinases with therapeutics for drug repurposing and development. 2013 , 7, 20	20
947	Kinotypes: stable species- and individual-specific profiles of cellular kinase activity. 2013 , 14, 854	15
946	Side-effects of protein kinase inhibitors on ion channels. 2013 , 38, 937-49	5
945	Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. 2013 , 12, 1723-31	44
944	Functional expression of the voltage-gated Na ⁺ -channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. 2013 , 126, 4939-49	65
943	Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor. 2013 , 69, 115-24	32
942	Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor. 2013 , 27, 213-24	35
941	Combination of biotransformation by P450 BM3 mutants with on-line post-column bioaffinity and mass spectrometric profiling as a novel strategy to diversify and characterize p38 β kinase inhibitors. 2013 , 4, 371-377	11
940	Biodistribution of ^{99m} Tc-sunitinib as a potential radiotracer for tumor hypoxia imaging. 2013 , 56, 392-5	32
939	Large-scale cytological profiling for functional analysis of bioactive compounds. 2013 , 9, 2604-17	28
938	An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. 2013 , 9, 2266-81	25
937	Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach: 1st Cancer Update. 2013 , 6, 35-48	20
936	Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. 2013 , 59, 283-95	34
935	Fluorescent sensors of protein kinases: from basics to biomedical applications. 2013 , 113, 217-74	25
934	Multiplexed visualization of dynamic signaling networks using genetically encoded fluorescent protein-based biosensors. 2013 , 465, 373-81	30
933	Active site profiling reveals coupling between domains in SRC-family kinases. 2013 , 9, 43-50	50

932	Why nature really chose phosphate. 2013 , 46, 1-132	215
931	Conformational coupling across the plasma membrane in activation of the EGF receptor. 2013 , 152, 543-56	337
930	Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2. 2013 , 1834, 1352-8	9
929	Histone acetyltransferases: Rising ancient counterparts to protein kinases. 2013 , 99, 98-111	54
928	An integrative approach for the large-scale identification of human genome kinases regulating cancer metastasis. 2013 , 9, 732-6	6
927	Ultrathin-yttrium phosphate-shelled polyacrylate-ferriferrous oxide magnetic microspheres for rapid and selective enrichment of phosphopeptides. 2013 , 1316, 62-8	14
926	Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings. 2013 , 41, 491-500	15
925	Amelioration of an undesired action of deguelin. 2013 , 74, 83-91	8
924	Throwing a monkey wrench in the motor: targeting DEXH/D box proteins with small molecule inhibitors. 2013 , 1829, 894-903	9
923	The identification of novel p38 β isoform selective kinase inhibitors having an unprecedented p38 β binding mode. 2013 , 23, 4120-6	14
922	Large-scale prediction of human kinase-inhibitor interactions using protein sequences and molecular topological structures. 2013 , 792, 10-8	20
921	Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP. 2013 , 8, 599-607	58
920	High-Throughput Screening in Agrochemical Research. 2013 , 1-20	3
919	Activity-based kinase profiling of approved tyrosine kinase inhibitors. 2013 , 18, 110-22	136
918	The role of PKC/ERK1/2 signaling in the anti-inflammatory effect of tetracyclic triterpene euphol on TPA-induced skin inflammation in mice. 2013 , 698, 413-20	53
917	Examining factors that influence erroneous phosphorylation site localization via competing fragmentation and rearrangement reactions during ion trap CID-MS/MS and -MS(3.). 2013 , 13, 964-73	16
916	The dynamic nature of the kinome. 2013 , 450, 1-8	75
915	Integration of phosphoproteomic, chemical, and biological strategies for the functional analysis of targeted protein phosphorylation. 2013 , 13, 424-37	20

914	Fluorescent biosensors - probing protein kinase function in cancer and drug discovery. 2013 , 1834, 1387-95	46
913	Biotinylated phosphoproteins from kinase-catalyzed biotinylation are stable to phosphatases: implications for phosphoproteomics. 2013 , 14, 381-7	14
912	Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. 2013 , 61, 84-94	40
911	Phosphopeptide microarrays for comparative proteomic profiling of cellular lysates. 2013 , 1002, 233-51	13
910	De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments. 2013 , 8, 1044-52	39
909	Deficiency of the RII β subunit of PKA affects locomotor activity and energy homeostasis in distinct neuronal populations. 2013 , 110, E1631-40	26
908	Distinct PKA and Epac compartmentalization in airway function and plasticity. 2013 , 137, 248-65	37
907	Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance. 2013 , 82, 506-19	5
906	Graphene oxide-peptide nanocomplex as a versatile fluorescence probe of protein kinase activity based on phosphorylation protection against carboxypeptidase digestion. 2013 , 85, 5746-54	82
905	The background, discovery and clinical development of BCR-ABL inhibitors. 2013 , 18, 992-1000	37
904	Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. 2013 , 88, 293-308	31
903	The molecular basis of targeting protein kinases in cancer therapeutics. 2013 , 23, 235-42	63
902	Hepatotoxicity of Immunosuppressive Drugs. 2013 , 569-591	7
901	Three-component assembly of structurally diverse 2-aminopyrimidine-5-carbonitriles. 2013 , 15, 370-8	15
900	Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. 2013 , 23, 3732-7	74
899	Diversity evolution and jump of Polo-like kinase 1 inhibitors. 2013 , 56, 1392-1401	13
898	Graphene based electrochemical biosensor for label-free measurement of the activity and inhibition of protein tyrosine kinase. 2013 , 138, 7212-7	17
897	Kinome-wide activity modeling from diverse public high-quality data sets. 2013 , 53, 27-38	41

896	Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. 2013 , 8, 2715-23	31
895	WITHDRAWN: QSAR and pharmacophore modeling of some benzimidazole derivatives as Protein Kinase CK2 Inhibitors. 2013 ,	9
894	Approaches to discover non-ATP site kinase inhibitors. 2013 , 4, 41-51	99
893	Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors. 2013 , 93, 215-9	19
892	CANCER-SPECIFIC GENE CARRIERS RESPONDING TO CANCER MICROENVIRONMENT: ACIDOSIS AND HYPER-ACTIVATED PROTEIN KINASES. 2013 , 25, 1340005	2
891	Improving the Prediction of Kinase Binding Affinity Using Homology Models. 2013 ,	1
890	The repertoires of ubiquitinating and deubiquitinating enzymes in eukaryotic genomes. 2013 , 30, 1172-87	54
889	KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms. 2013 , 41, D430-40	21
888	Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. 2013 , 2013, 536529	17
887	Using existing drugs as leads for broad spectrum anthelmintics targeting protein kinases. 2013 , 9, e1003149	32
886	Combinatorial clustering of residue position subsets predicts inhibitor affinity across the human kinome. 2013 , 9, e1003087	10
885	Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. 2013 , 110, 4045-50	171
884	Encyclopedia of Malaria. 2013 , 1-14	
883	Aiming for the outliers: cancer precision medicine through targeting kinases with extreme expression. 2013 , 3, 252-4	2
882	EP2 receptor signaling pathways regulate classical activation of microglia. 2013 , 288, 9293-302	79
881	Rational design of protein kinase inhibitors. 2013 , 29, 339-347	3
880	Structure and mechanism of non-histone protein acetyltransferase enzymes. 2013 , 280, 5570-81	49
879	Bioanalytical method development, validation and quantification of dorsomorphin in rat plasma by LC-MS/MS. 2013 , 27, 1018-26	1

878	Viewing serine/threonine protein phosphatases through the eyes of drug designers. 2013 , 280, 4739-60	48
877	From on-target to off-target activity: identification and optimisation of <i>Trypanosoma brucei</i> GSK3 inhibitors and their characterisation as anti- <i>Trypanosoma brucei</i> drug discovery lead molecules. 2013 , 8, 1127-37	24
876	Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics. 2013 , 12, 2969-80	30
875	Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads. 2013 , 11, 44-51	
874	Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. 2013 , 109, 2607-18	29
873	Calcium-Dependent Protein Kinases of Apicomplexan Parasites as Drug Targets. 2013 , 293-316	1
872	A unified approach to the important protein kinase inhibitor balanol and a proposed analogue. 2013 , 9, 2910-5	9
871	Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors. 2013 , 6, 48-55	1
870	Structure of N-(3,4-Dimethoxyphenyl)pyrido[3,2:4,5]-thieno[3,2-d]pyrimidin-4-amine, a New Inhibitor of CLK1 and DYRK1A Kinases. 2013 , 2013, 1-4	
869	The drug discovery process: General principles and some case histories. 2013 , 43-56	
868	Site-Directed Mutagenesis in the Research of Protein Kinases - The Case of Protein Kinase CK2. 2013 ,	
867	The shared crosstalk of multiple pathways involved in the inflammation between rheumatoid arthritis and coronary artery disease based on a digital gene expression profile. 2014 , 9, e113659	8
866	Peptide Arrays for Kinome Analysis of Livestock Species. 2014 , 1, 4	10
865	Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. 2014 , 7, 32	56
864	3-Aminothiophene-2-acylhydrazones: non-toxic, analgesic and anti-inflammatory lead-candidates. 2014 , 19, 8456-71	8
863	Protein phosphatase 1 and its complexes in carcinogenesis. 2014 , 14, 2-29	19
862	Stopping epileptogenesis dead in its tracks. 2014 , 14, 163-4	
861	Quick evaluation of kinase inhibitors by surface plasmon resonance using single-site specifically biotinylated kinases. 2014 , 19, 453-61	7

860	Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors. 2014 , 29, 69-80	8
859	A structural atlas of kinases inhibited by clinically approved drugs. 2014 , 548, 23-67	32
858	New insights into schizophrenia disease genes interactome in the human brain: emerging targets and therapeutic implications in the postgenomics era. 2014 , 18, 754-66	7
857	Homopharma: a new concept for exploring the molecular binding mechanisms and drug repurposing. 2014 , 15 Suppl 9, S8	6
856	Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. 2014 , 111, 1780-7	50
855	The epidermal growth factor receptor critically regulates endometrial function during early pregnancy. 2014 , 10, e1004451	57
854	Identification of extracellular signal-regulated kinase 1 (ERK1) direct substrates using stable isotope labeled kinase assay-linked phosphoproteomics. 2014 , 13, 3199-210	32
853	Small molecule gated split-tyrosine phosphatases and orthogonal split-tyrosine kinases. 2014 , 136, 17078-86	20
852	Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents. 2014 , 22, 6953-60	21
851	Fragment-based approaches to the discovery of kinase inhibitors. 2014 , 548, 69-92	9
850	The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles. 2014 , 548, 117-46	14
849	Substrate Activity Screening with Kinases: Discovery of Small-Molecule Substrate-Competitive c-Src Inhibitors. 2014 , 126, 7130-7133	4
848	Role of Desolvation in Thermodynamics and Kinetics of Ligand Binding to a Kinase. 2014 , 10, 5696-5705	44
847	Simultaneous inhibition assay for human and microbial kinases via MALDI-MS/MS. 2014 , 15, 587-94	5
846	Fluorescent biosensors for high throughput screening of protein kinase inhibitors. 2014 , 9, 253-65	19
845	CHAPTER 5:Designed Macrocyclic Kinase Inhibitors. 2014 , 141-205	6
844	The Multifunctional Protein Kinase C- β in Cancer Development and Progression. 2014 , 6, 860-78	39
843	A QM/MM study of the associative mechanism for the phosphorylation reaction catalyzed by protein kinase A and its D166A mutant. 2014 , 28, 1077-91	11

842	Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression. 2014 , 8, 74	16
841	A method for screening and validation of resistant mutations against kinase inhibitors. 2014 ,	2
840	Organometallic Complexes as Enzyme Inhibitors: A Conceptual Overview. 2014 , 1-42	
839	Probing SH2-domains using Inhibitor Affinity Purification (IAP). 2014 , 12, 41	10
838	Damnacanthal, an effective inhibitor of LIM-kinase, inhibits cell migration and invasion. 2014 , 25, 828-40	29
837	Systems kinomics for characterizing host responses to high-consequence pathogens at the NIH/NIAID Integrated Research Facility-Frederick. 2014 , 71, 190-98	3
836	KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. 2014 , 57, 249-77	179
835	Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. 2014 , 22, 1909-15	10
834	Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. 2014 , 426, 423-35	62
833	The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. 2014 , 54, 9-26	200
832	Genome of the human hookworm <i>Necator americanus</i> . 2014 , 46, 261-269	139
831	Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and CTNNA3 are associated with disease severity and treatment response in childhood asthma. 2014 , 66, 143-51	22
830	Scaffold mining of kinase hinge binders in crystal structure database. 2014 , 28, 13-23	31
829	In vitro infection of bovine monocytes with <i>Mycoplasma bovis</i> delays apoptosis and suppresses production of gamma interferon and tumor necrosis factor alpha but not interleukin-10. 2014 , 82, 62-71	45
828	Microfluidic bead-based sensing platform for monitoring kinase activity. 2014 , 57, 1-9	18
827	A highly efficient TFOH-assisted alkylation of azaindoles with β -phenylethanol. 2014 , 55, 2745-2748	2
826	Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. 2014 , 176, 1-10	128
825	Parameterization of DFTB3/3OB for Sulfur and Phosphorus for Chemical and Biological Applications. 2014 , 10, 1518-1537	195

824	A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity. 2014 , 10, 127-32	108
823	Drugs for allosteric sites on receptors. 2014 , 54, 165-84	166
822	The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 63-79	64.1 595
821	Rapid profiling of protein kinase inhibitors by quantitative proteomics. 2014 , 5, 363-369	17
820	Multi-algorithm and multi-model based drug target prediction and web server. 2014 , 35, 419-31	5
819	Mass spectrometry for proteomics-based investigation. 2014 , 806, 1-32	11
818	A mix-and-read fluorescence strategy for the switch-on probing of kinase activity based on an aptameric-peptide/graphene-oxide platform. 2014 , 9, 2560-7	4
817	When tight is too tight: Dasatinib and its lower affinity analogue for profiling kinase inhibitors in a three-hybrid split-luciferase system. 2014 , 5, 328-332	1
816	Selective G-quadruplex stabilizers: Schiff-base metal complexes with anticancer activity. 2014 , 4, 33245-33256	62
815	Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. 2014 , 5, 1266-1279	19
814	Graphene oxide for fluorescence-mediated enzymatic activity assays. 2014 , 2, 2452-2460	22
813	In vitro selection of a peptide aptamer that potentiates inhibition of cyclin-dependent kinase 2 by purvalanol. 2014 , 5, 1400-1403	11
812	Cyclic-AMP-dependent protein kinase (PKA) activity assay based on FRET between cationic conjugated polymer and chromophore-labeled peptide. 2014 , 139, 4710-6	9
811	A phosphohistidine proteomics strategy based on elucidation of a unique gas-phase phosphopeptide fragmentation mechanism. 2014 , 136, 12899-911	53
810	Influenza, a One Health paradigm--novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential. 2014 , 304, 894-901	16
809	p38MAPK plays a crucial role in stromal-mediated tumorigenesis. 2014 , 4, 716-29	90
808	Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. 2014 , 21, 848-53	78
807	Rheumatoid Arthritis: Disease Pathophysiology. 2014 , 215-229	

806	An excimer-based, turn-on fluorescent sensor for the selective detection of diphosphorylated proteins in aqueous solution and polyacrylamide gels. 2014 , 136, 1234-7	52
805	The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases. 2014 , 740, 88-96	3
804	Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells. 2014 , 24, 3748-52	5
803	Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation. 2014 , 57, 6834-44	22
802	Bivalent inhibitors of protein kinases. 2014 , 49, 102-15	42
801	2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites. 2014 , 57, 7485-98	25
800	Virtual screening of PRK1 inhibitors: ensemble docking, rescoring using binding free energy calculation and QSAR model development. 2014 , 54, 138-50	30
799	Using thermodynamic integration MD simulation to compute relative protein-ligand binding free energy of a GSK3 β kinase inhibitor and its analogs. 2014 , 51, 37-49	23
798	The Changing Face of Innovation in Drug Discovery. 2014 , 31-56	1
797	In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics. 2014 , 53, 1-12	5
796	New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics. 2014 , 13, 2445-52	17
795	A gold nanoparticles colorimetric assay for label-free detection of protein kinase activity based on phosphorylation protection against exopeptidase cleavage. 2014 , 53, 295-300	63
794	Recent advances in the discovery of small molecules targeting exchange proteins directly activated by cAMP (EPAC). 2014 , 57, 3651-65	34
793	Evaluation of serum phosphopeptides as potential cancer biomarkers by mass spectrometric absolute quantification. 2014 , 125, 411-7	19
792	Fluorescent detection of protein kinase based on positively charged gold nanoparticles. 2014 , 128, 360-5	15
791	Discovery of 4-anilino β -carboline as novel Brk inhibitors. 2014 , 24, 1948-51	13
790	Conventional protein kinase C isoforms mediate phorbol ester-induced lysophosphatidic acid LPA1 receptor phosphorylation. 2014 , 723, 124-30	9
789	BRAF inhibitors: From the laboratory to clinical trials. 2014 , 90, 220-32	30

788	Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors. 2014 , 53, 7010-3	16
787	Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. 2014 , 28, 551-82	15
786	Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. 2014 , 50, 2020-36	208
785	ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. 2014 , 87, 42-59	133
784	Amplified electrochemical detection of protein kinase activity based on gold nanoparticles/multi-walled carbon nanotubes nanohybrids. 2014 , 129, 328-35	31
783	Pyridinyl imidazole compounds interfere with melanosomes sorting through the inhibition of cyclin G-associated Kinase, a regulator of cathepsins maturation. 2014 , 26, 716-23	8
782	Screening of protein kinase inhibitors in natural extracts by capillary electrophoresis combined with liquid chromatography-tandem mass spectrometry. 2014 , 1337, 188-93	27
781	Prospects for new antibiotics: a molecule-centered perspective. 2014 , 67, 7-22	248
780	Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library. 2015 , 10, 1809-20	13
779	Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain. 2015 , 20, 860-70	7
778	Accurate label-free reaction kinetics determination using initial rate heat measurements. 2015 , 5, 16380	6
777	Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors. 2015 , 5, 13934	12
776	Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. 2015 , 5, 16750	21
775	Overview: General Principles. 2015 , 15-28	
774	Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. 2015 , 5, 16924	40
773	Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-schistosome drug targets. 2015 , 5, 17759	32
772	PSEA: Kinase-specific prediction and analysis of human phosphorylation substrates. 2014 , 4, 4524	22
771	Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). 2015 , 16 Suppl 8, S8	0

770	A Cell-Permeable ATP Analogue for Kinase-Catalyzed Biotinylation. 2015 , 127, 9754-9757	5
769	A highly sensitive square wave voltammetry based biosensor for kinase activity measurements. 2015 , 104, 515-20	8
768	Real-Time Monitoring of Phosphorylation Kinetics with Self-Assembled Nano-oscillators. 2015 , 127, 2568-2572	4
767	Advances in capillary electrophoresis for miniaturizing assays on kinase enzymes for drug discovery. 2015 , 36, 2768-2797	16
766	Clickable 5'- \square ferrocenyl adenosine triphosphate bioconjugates in kinase-catalyzed phosphorylations. 2015 , 21, 4988-99	12
765	Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors. 2015 , 127, 11920-11925	4
764	A Cell-Permeable ATP Analogue for Kinase-Catalyzed Biotinylation. 2015 , 54, 9618-21	15
763	Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors. 2015 , 54, 11754-9	36
762	Screening of Microbial Extracts for Anticancer Compounds Using Streptomyces Kinase Inhibitor Assay. 2015 , 10, 1934578X1501000	3
761	Diverse Molecular Targets for Chalcones with Varied Bioactivities. 2015 , 5, 388-404	42
760	Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. 2015 , 6, 26142-60	50
759	Evolution and intelligent design in drug development. 2015 , 2, 27	7
758	[Screening marine resources to find novel chemical inhibitors of disease-relevant protein kinases]. 2015 , 31, 538-45	
757	Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein Phosphatases. 2015 , 6, 270	30
756	Phosphorylation, Signaling, and Cancer: Targets and Targeting. 2015 , 2015, 601543	8
755	Proteomics in cancer biomarkers discovery: challenges and applications. 2015 , 2015, 321370	61
754	References. 2015 , 421-454	
753	Effect of Feature Selection on Kinase Classification Models. 2015 , 81-86	1

752	Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. 2015 , 13, 638-49	48
751	Label-free fluorescence detection of kinase activity using a gold nanoparticle based indicator displacement assay. 2015 , 13, 1198-203	7
750	Adaptability in protein structures: structural dynamics and implications in ligand design. 2015 , 33, 298-321	6
749	Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors. 2015 , 92, 124-34	31
748	Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics. 2015 , 115, 2045-108	223
747	Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. 2015 , 6, 53-7	37
746	Bioinformatics in protein kinases regulatory network and drug discovery. 2015 , 262, 147-56	14
745	Recent advances in cancer therapeutics. 2015 , 54, 1-63	21
744	Rapid evaluation of tyrosine kinase activity of membrane-integrated human epidermal growth factor receptor using the yeast G β recruitment system. 2015 , 4, 421-9	4
743	Optimized chemical proteomics assay for kinase inhibitor profiling. 2015 , 14, 1574-86	76
742	25 years of small molecular weight kinase inhibitors: potentials and limitations. 2015 , 87, 766-75	102
741	Ten things you should know about protein kinases: IUPHAR Review 14. 2015 , 172, 2675-700	180
740	Interactions of the antimalarial amodiaquine with lipid model membranes. 2015 , 186, 68-78	15
739	Real-time monitoring of phosphorylation kinetics with self-assembled nano-oscillators. 2015 , 54, 2538-42	32
738	Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases. 2015 , 195, 30-6	3
737	Novel pyrrole derivatives as selective CHK1 inhibitors: design, regioselective synthesis and molecular modeling. 2015 , 6, 852-859	9
736	Membrane-drug interactions studied using model membrane systems. 2015 , 22, 714-8	51
735	Tumor accumulation of protein kinase-responsive gene carrier/DNA polyplex stabilized by alkanethiol for intravenous injection. 2015 , 26, 657-68	1

734	Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity. 2015 , 37, 1643-51.e3	11
733	Multimodal electrochemical and nanoplasmonic biosensors using ferrocene-crowned nanoparticles for kinase drug discovery applications. 2015 , 57, 70-73	15
732	Application of chemical biology in target identification and drug discovery. 2015 , 38, 1642-50	10
731	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. 2015 , 132, 96-168	282
730	Kinase-interacting substrate screening is a novel method to identify kinase substrates. 2015 , 209, 895-912	49
729	A dual-potential electrochemiluminescence ratiometric approach based on graphene quantum dots and luminol for highly sensitive detection of protein kinase activity. 2015 , 51, 12669-72	76
728	The antinociceptive effects of the tetracyclic triterpene euphol in inflammatory and neuropathic pain models: The potential role of PKC δ . 2015 , 303, 126-37	38
727	Revealing the favorable dissociation pathway of type II kinase inhibitors via enhanced sampling simulations and two-end-state calculations. 2015 , 5, 8457	59
726	Synthetic approaches to protein phosphorylation. 2015 , 28, 115-22	58
725	A historical overview of protein kinases and their targeted small molecule inhibitors. 2015 , 100, 1-23	288
724	Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration. 2015 , 6, 898-901	10
723	Targeting cancer with kinase inhibitors. 2015 , 125, 1780-9	284
722	Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for <i>Trypanosoma brucei</i> . 2015 , 20, 70-81	22
721	Discovery of 3,3a,4,5-tetrahydro-2H-benzo[g]indazole containing quinoxaline derivatives as novel EGFR/HER-2 dual inhibitors. 2015 , 5, 24814-24823	11
720	Plasmonic ruler on field-effect devices for kinase drug discovery applications. 2015 , 71, 121-128	20
719	A highly sensitive electrochemiluminescence assay for protein kinase based on double-quenching of graphene quantum dots by G-quadruplex-hemin and gold nanoparticles. 2015 , 70, 54-60	49
718	The ABC of protein kinase conformations. 2015 , 1854, 1555-66	48
717	Detailed atomistic molecular modeling of a potent type II inhibitor. 2015 , 26, 1125-1137	3

716	Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3). 2015 , 29, 619-41	3
715	Privileged scaffolds in lead generation. 2015 , 10, 781-90	51
714	A mechanism of global shape-dependent recognition and phosphorylation of filamin by protein kinase A. 2015 , 290, 8527-38	12
713	Selective detection of tyrosine-containing proximally phosphorylated motifs using an antenna-free Tb ³⁺ luminescent sensor. 2015 , 51, 6675-7	7
712	Protein Kinase Inhibitors from Microorganisms. 2015 , 44, 403-445	2
711	Design and evaluation of a real-time activity probe for focal adhesion kinase. 2015 , 897, 62-8	9
710	A Proteomic Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues. 2015 , 10, 2827-40	12
709	Recent findings and technological advances in phosphoproteomics for cells and tissues. 2015 , 12, 469-87	63
708	A real-time, fluorescence-based assay for Rho-associated protein kinase activity. 2015 , 891, 284-90	10
707	Interaction between phosphodiesterases in the regulation of the cardiac β -adrenergic pathway. 2015 , 88, 29-38	18
706	Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects. 2015 , 12, 1939-49	26
705	Two hydrophobic residues can determine the specificity of mitogen-activated protein kinase docking interactions. 2015 , 290, 26661-74	13
704	An integrated flow and microwave approach to a broad spectrum protein kinase inhibitor. 2015 , 5, 93433-93437	
703	Integrating proteomics with electrochemistry for identifying kinase biomarkers. 2015 , 6, 4756-4766	21
702	Modeling Signaling Networks to Advance New Cancer Therapies. 2015 , 17, 143-63	24
701	Stereoselective recognition of the Ac-Glu-Tyr-OH dipeptide by pseudopeptidic cages. 2015 , 13, 11721-31	29
700	Gold-Catalyzed Cycloisomerization and Diels-Alder Reaction of 1,6-Diyne Esters with Alkenes and Diazenes to Hydronaphthalenes and -cinnolines. 2015 , 17, 4176-9	51
699	Drosophila glucose screening identifies Ck1alpha as a regulator of mammalian glucose metabolism. 2015 , 6, 7102	55

698	Uncovering dynamic phosphorylation signaling using mass spectrometry. 2015 , 391, 123-138	3
697	Kinase hinge binding scaffolds and their hydrogen bond patterns. 2015 , 23, 6520-7	82
696	Property-based characterization of kinase-like ligand space for library design and virtual screening. 2015 , 6, 1898-1904	4
695	PASS Targets: Ligand-based multi-target computational system based on a public data and naïve Bayes approach. 2015 , 26, 783-93	32
694	Protein kinase profiling assays: a technology review. 2015 , 18, 1-8	31
693	Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. 2015 , 10, 175-89	35
692	Inhibition of CREB phosphorylation by conjugates of adenosine analogues and arginine-rich peptides, inhibitors of PKA catalytic subunit. 2015 , 16, 312-9	6
691	Quantitative proteomics of kinase inhibitor targets and mechanisms. 2015 , 10, 201-12	23
690	Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. 2015 , 59, 1088-99	258
689	DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. 2015 , 10, 269-78	22
688	PINK1 and Parkin mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. 2015 , 282, 215-23	81
687	Array-based proteomic approaches to study signal transduction pathways: prospects, merits and challenges. 2015 , 15, 218-31	11
686	Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors. 2015 , 10, 279-88	19
685	Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors. 2015 , 30, 290-8	1
684	Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects. 2015 , 6, 24-50	74
683	New series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives: synthesis, antitumor activity, EGFR tyrosine kinase inhibitory activity and molecular modeling studies. 2015 , 24, 860-878	24
682	Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease. 2016 , 2016, 7351985	20
681	Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer. 2016 , 3,	7

680	Emerging drug resistance in <i>Plasmodium falciparum</i> : A review of well-characterized drug targets for novel antimalarial chemotherapy. 2016 , 6, 581-588	7
679	Predicting Molecular Targets for Small-Molecule Drugs with a Ligand-Based Interaction Fingerprint Approach. 2016 , 11, 1352-61	14
678	Allosteric modulators of MEK1: drug design and discovery. 2016 , 88, 485-97	12
677	Mapping cancer signaling networks by an integrated multiplexed tissue imaging platform. 2016 , 04, 174-193	2
676	Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. 2016 , 68, 788-815	77
675	Screening applications in drug discovery based on microfluidic technology. 2016 , 10, 011502	32
674	<i>Dictyocaulus viviparus</i> genome, variome and transcriptome elucidate lungworm biology and support future intervention. 2016 , 6, 20316	17
673	Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. 2016 , 13, 4	34
672	DNA Replication Stress Phosphoproteome Profiles Reveal Novel Functional Phosphorylation Sites on Xrs2 in <i>Saccharomyces cerevisiae</i> . 2016 , 203, 353-68	2
671	Zirconium-metalloporphyrin frameworks as a three-in-one platform possessing oxygen nanocage, electron media, and bonding site for electrochemiluminescence protein kinase activity assay. 2016 , 8, 11649-57	45
670	Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt. 2016 , 24, 3396-405	8
669	Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010-2015). 2016 , 26, 607-16	5
668	Flow Cytometry Enables Multiplexed Measurements of Genetically Encoded Intramolecular FRET Sensors Suitable for Screening. 2016 , 21, 535-47	11
667	Innovative computer-aided methods for the discovery of new kinase ligands. 2016 , 8, 509-26	12
666	Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines. 2016 , 55, 4595-605	35
665	Metabolite concentrations, fluxes and free energies imply efficient enzyme usage. 2016 , 12, 482-9	205
664	Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. 2016 , 59, 4697-710	30
663	Integration of Global Analyses of Host Molecular Responses with Clinical Data To Evaluate Pathogenesis and Advance Therapies for Emerging and Re-emerging Viral Infections. 2016 , 2, 787-799	9

- 662 Dehydrosulfurative C-N Cross-Coupling and Concomitant Oxidative Dehydrogenation for One-Step Synthesis of 2-Aryl(alkyl)aminopyrimidines from 3,4-Dihydropyrimidin-1H-2-thiones. **2016**, 18, 5154-5157 17
- 661 Rational design of multi-targeting ruthenium- and platinum-based anticancer complexes. **2016**, 59, 1240-1249 13
- 660 Low-cost iron oxide magnetic nanoclusters affinity probe for the enrichment of endogenous phosphopeptides in human saliva. **2016**, 6, 96210-96222 23
- 659 Unprecedentedly Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?. **2016**, 56, 1654-75 35
- 658 Design and synthesis of novel protein kinase R (PKR) inhibitors. **2016**, 20, 805-819 5
- 657 Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK. **2016**, 24, 4652-4659 17
- 656 Phospholipid Ozonation Products Activate the 5-Lipoxygenase Pathway in Macrophages. **2016**, 29, 1355-64 6
- 655 A Simple and Sensitive Assay for Protein Kinase a Using Single-walled Carbon Nanotube Field-Effect Transistor. **2016**, 37, 1167-1168 5
- 654 Oxindole: A chemical prism carrying plethora of therapeutic benefits. **2016**, 123, 858-894 151
- 653 Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. **2016**, 59, 9305-9320 39
- 652 Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1. **2016**, 21, 1049-1058 12
- 651 New Magnetic Graphitized Carbon Black TiO Composite for Phosphopeptide Selective Enrichment in Shotgun Phosphoproteomics. **2016**, 88, 12043-12050 44
- 650 Roles and regulation of protein phosphatase 2A (PP2A) in the heart. **2016**, 101, 127-133 44
- 649 Rationalization of physicochemical characters and structural determinants of benzimidazole analogues as casein kinase 2 inhibitors: computational approach. **2016**, 5, 1 3
- 648 Aptamer based lysozyme assay using fluorescent CuInS₂ quantum dots and graphene oxide, and its application to inhibitor screening. **2016**, 183, 2907-2916 9
- 647 Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules. **2016**, 116, 9001-90 510
- 646 Atomic force microscopy characterization of kinase-mediated phosphorylation of a peptide monolayer. **2016**, 6, 36793 5
- 645 Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?. **2016**, 16, 62 29

644	The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. 2016 , 59, 10084-10099	52
643	Global Phosphoproteomic Analysis Reveals the Involvement of Phosphorylation in Aflatoxins Biosynthesis in the Pathogenic Fungus <i>Aspergillus flavus</i> . 2016 , 6, 34078	23
642	Zirconium-Based Porphyrinic Metal-Organic Framework (PCN-222): Enhanced Photoelectrochemical Response and Its Application for Label-Free Phosphoprotein Detection. 2016 , 88, 11207-11212	106
641	A CIEF-LIF method for simultaneous analysis of multiple protein kinases and screening of inhibitors. 2016 , 37, 2075-82	6
640	Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain. 2016 , 21, 350-7	3
639	Design and synthesis of new potent PTP1B inhibitors with the skeleton of 2-substituted imino-3-substituted-5-heteroarylidene-1,3-thiazolidine-4-one: Part I. 2016 , 122, 756-769	22
638	Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015). 2016 , 26, 917-32	21
637	Discovery and antiplatelet activity of a selective PI3K β inhibitor (MIPS-9922). 2016 , 122, 339-351	22
636	Biophysical investigation and conformational analysis of p38 β kinase inhibitor doramapimod and its analogues. 2016 , 7, 1421-1428	3
635	Calcium/calmodulin-dependent protein kinase IV: A multifunctional enzyme and potential therapeutic target. 2016 , 121, 54-65	42
634	PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. 2016 , 109, 314-41	296
633	Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network. 2016 , 91, 215-27	24
632	The Effector Protein BPE005 from <i>Brucella abortus</i> Induces Collagen Deposition and Matrix Metalloproteinase 9 Downmodulation via Transforming Growth Factor β in Hepatic Stellate Cells. 2016 , 84, 598-606	13
631	Using Phos-Tag in Western Blotting Analysis to Evaluate Protein Phosphorylation. 2016 , 1397, 267-277	14
630	Phosphorylation-mediated regulation of the <i>Staphylococcus aureus</i> secreted tyrosine phosphatase PtpA. 2016 , 469, 619-25	6
629	Dye-Sensitized and Localized Surface Plasmon Resonance Enhanced Visible-Light Photoelectrochemical Biosensors for Highly Sensitive Analysis of Protein Kinase Activity. 2016 , 88, 922-9	82
628	Bioluminescent kinase strips: A novel approach to targeted and flexible kinase inhibitor profiling. 2016 , 495, 9-20	4
627	Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. 2016 , 112, 298-346	38

626	Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015). 2016 , 26, 389-407	8
625	Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors. 2016 , 11, 1245-54	58
624	From the primordial soup to self-driving cars: standards and their role in natural and technological innovation. 2016 , 13, 20151086	4
623	Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation. 2016 , 112, 347-366	18
622	Modeling the effect of pathogenic mutations on the conformational landscape of protein kinases. 2016 , 37, 108-14	13
621	KLIFS: a structural kinase-ligand interaction database. 2016 , 44, D365-71	98
620	From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity. 2016 , 60, 2822-33	36
619	Design, synthesis and biological evaluation of indazolepyrimidine based derivatives as anticancer agents with anti-angiogenic and antiproliferative activities. 2016 , 7, 881-899	18
618	How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations. 2016 , 138, 4608-15	26
617	Identification and Visualization of Kinase-Specific Subpockets. 2016 , 56, 335-46	14
616	Solution NMR Spectroscopy for the Study of Enzyme Allostery. 2016 , 116, 6323-69	79
615	Recent advances in iron complexes as potential anticancer agents. 2016 , 40, 1063-1090	96
614	Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors. 2016 , 7, 224-229	3
613	A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors. 2016 , 14, 963-9	16
612	Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. 2016 , 103, 26-48	397
611	Discovery of nitroaryl urea derivatives with antiproliferative properties. 2016 , 31, 608-18	8
610	Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity. 2016 , 11, 121-31	12
609	Proteomics and drug discovery in cancer. 2016 , 21, 264-77	23

608	Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. 2016 , 24, 192-211	11
607	In vitro anti-inflammatory components isolated from the carnivorous plant <i>Nepenthes mirabilis</i> (Lour.) Rafarin. 2016 , 54, 588-94	15
606	Energy Transfer with Semiconductor Quantum Dot Bioconjugates: A Versatile Platform for Biosensing, Energy Harvesting, and Other Developing Applications. 2017 , 117, 536-711	439
605	Pseudokinases: update on their functions and evaluation as new drug targets. 2017 , 9, 245-265	49
604	Multi-step virtual screening to develop selective DYRK1A inhibitors. 2017 , 72, 229-239	7
603	Akt3 is a privileged first responder in isozyme-specific electrophile response. 2017 , 13, 333-338	39
602	Staurosporine Induces Filamentation in the Human Fungal Pathogen via Signaling through Cyr1 and Protein Kinase A. 2017 , 2,	14
601	The effect of magnesium ions on triphosphate hydrolysis. 2017 , 89, 715-727	16
600	Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family. 2017 , 25, 2657-2665	32
599	Antiepileptic action of c-Jun N-terminal kinase (JNK) inhibition in an animal model of temporal lobe epilepsy. 2017 , 349, 35-47	20
598	Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice. 2017 , 129, 246-256	8
597	Fast NMR-Based Determination of the 3D Structure of the Binding Site of Protein-Ligand Complexes with Weak Affinity Binders. 2017 , 129, 5292-5295	1
596	A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain. 2017 , 64, e26551	21
595	Regulation of cardiac gap junctions by protein phosphatases. 2017 , 107, 52-57	17
594	The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery. 2017 , 60, 6781-6827	77
593	New Synthetic Methods for Phosphate Labeling. 2017 , 375, 51	6
592	Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation. 2017 , 16, 1831-1842	9
591	Kinase-templated abiotic reaction. 2017 , 8, 5119-5125	12

- 590 Characterization and enzymatic properties of protein kinase ACR4 from *Arabidopsis thaliana*. **2017**, 489, 270-274 2
- 589 Tissue-Specific Signaling Networks Rewired by Major Somatic Mutations in Human Cancer Revealed by Proteome-Wide Discovery. **2017**, 77, 2810-2821 22
- 588 Structure-Based Target-Specific Screening Leads to Small-Molecule CaMKII Inhibitors. **2017**, 12, 660-677 7
- 587 Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analogues as potent EPAC antagonists. **2017**, 134, 62-71 7
- 586 Fast NMR-Based Determination of the 3D Structure of the Binding Site of Protein-Ligand Complexes with Weak Affinity Binders. **2017**, 56, 5208-5211 17
- 585 Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. **2017**, 72, 116-122 18
- 584 Engineering Small Molecule Responsive Split Protein Kinases. **2017**, 1596, 307-319
- 583 Binding studies and biological evaluation of β -carotene as a potential inhibitor of human calcium/calmodulin-dependent protein kinase IV. **2017**, 96, 161-170 52
- 582 Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective. **2017**, 89, 834-845 14
- 581 Translation system engineering in *Escherichia coli* enhances non-canonical amino acid incorporation into proteins. **2017**, 114, 1074-1086 37
- 580 Prediction of Protein Kinase-Ligand Interactions through 2.5D Kinochemometrics. **2017**, 57, 93-101 11
- 579 Effect of benzocaine and propranolol on phospholipid-based bilayers. **2017**, 19, 32057-32071 11
- 578 Development of the first model of a phosphorylated, ATP/Mg-containing B-Raf monomer by molecular dynamics simulations: a tool for structure-based design. **2017**, 19, 31177-31185 2
- 577 The π - and σ -Holes. The Halogen and Tetrel Bondings: Their Nature, Importance and Chemical, Biological and Medicinal Implications. **2017**, 2, 9094-9112 34
- 576 Computational Modeling of Cyclic Nucleotide Signaling Mechanisms in Cardiac Myocytes. **2017**, 175-213
- 575 Towards sensitive, high-throughput, biomolecular assays based on fluorescence lifetime. **2017**, 5, 034002 11
- 574 Covalent Lipid Pocket Ligands Targeting p38 β -MAPK Mutants. **2017**, 56, 13232-13236 13
- 573 Kovalente Liganden zur Adressierung einer lipophilen Bindetasche in der MAPK p38 β . **2017**, 129, 13415-13419

572	A Split-Abl Kinase for Direct Activation in Cells. 2017 , 24, 1250-1258.e4	10
571	Promiscuity of inhibitors of human protein kinases at varying data confidence levels and test frequencies. 2017 , 7, 41265-41271	20
570	Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1. 2017 , 34, 176	6
569	Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single-Molecule Spectroscopy. 2017 , 56, 11409-11414	23
568	Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells. 2017 , 3, e00318	7
567	Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. 2017 , 36, 6501-6507	12
566	Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single-Molecule Spectroscopy. 2017 , 129, 11567-11572	0
565	Computational evaluation of 2-amino-5-sulphonamido-1,3,4-thiadiazoles as human carbonic anhydrase-IX inhibitors: an insight into the structural requirement for the anticancer activity against HEK 293. 2017 , 26, 2272-2292	0
564	Label-Free Homogeneous Electrochemical Sensing Platform for Protein Kinase Assay Based on Carboxypeptidase Y-Assisted Peptide Cleavage and Vertically Ordered Mesoporous Silica Films. 2017 , 89, 9062-9068	26
563	Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors. 2017 , 57, 2152-2160	9
562	Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. 2017 , 142, 271-289	105
561	Identifying Inhibitors of Inflammation: A Novel High-Throughput MALDI-TOF Screening Assay for Salt-Inducible Kinases (SIKs). 2017 , 22, 1193-1202	34
560	Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling. 2017 , 171, 1545-1558.e18	107
559	Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. 2017 , 77, 1935-1966	124
558	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. 2017 , 102, 1401-1412	17
557	Applications of Nonenzymatic Catalysts to the Alteration of Natural Products. 2017 , 117, 11894-11951	120
556	Pharmacogenomics and Pharmacogenetics. 2017 , 151-166	1
555	Therapeutic Potential of Small Molecule Inhibitors. 2017 , 118, 959-961	13

554	Structural-conformational aspects of tRNA complexation with chloroethyl nitrosourea derivatives: A molecular modeling and spectroscopic investigation. 2017 , 166, 1-11	5
553	Profiling Prediction of Kinase Inhibitors: Toward the Virtual Assay. 2017 , 60, 474-485	55
552	Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors. 2017 , 25, 389-396	15
551	Design, synthesis, and biological evaluation of pyrimidine derivatives as potential inhibitors of human calcium/calmodulin-dependent protein kinase IV. 2017 , 89, 741-754	23
550	Emerging Methods in Chemoproteomics with Relevance to Drug Discovery. 2017 , 1513, 11-22	15
549	A graphene oxide-based multiplexed fluorescence assay for the detection of protein kinase activity in cell lysates and the evaluation of protein kinase inhibition. 2017 , 238, 908-916	9
548	Phosphosite-specific regulation of the oxidative-stress response of <i>Paracoccidioides brasiliensis</i> : a shotgun phosphoproteomic analysis. 2017 , 19, 34-46	6
547	Clarifying binding difference of ATP and ADP to extracellular signal-regulated kinase 2 by using molecular dynamics simulations. 2017 , 89, 548-558	11
546	The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications. 2017 , 46, 7706-7756	240
545	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. 2017 , 1-38	1
544	EDITORIAL: Advances in Developing Versatile Tools for the Discovery of Novel Therapeutics. 2017 , 17, 2233-2234	1
543	Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. 2017 , 18,	16
542	The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis. 2017 , 18,	15
541	Protein Kinase Targets in Breast Cancer. 2017 , 18,	36
540	Autophosphorylation and Cross-Phosphorylation of Protein Kinases from the Crenarchaeon. 2017 , 8, 2173	5
539	Systematic exploration of multiple drug binding sites. 2017 , 9, 65	9
538	Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways. 2017 , 8, 5800-5813	14
537	Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair. 2017 , 18,	41

536	Fluorescence-Based Chemosensors for the Detection of Biologically Relevant Phosphates in Water. 2017 , 113-160	
535	Simple and Sensitive Method for Determination of Protein Kinase Activity Based on Surface Charge Change of Peptide-Modified Gold Nanoparticles As Substrates. 2018 , 90, 3871-3877	11
534	Inhibition of protein kinase A affects <i>Paracoccidioides lutzii</i> dimorphism. 2018 , 113, 1214-1220	3
533	Aralkyl selenoglycosides and related selenosugars in acetylated form activate protein phosphatase-1 and -2A. 2018 , 26, 1875-1884	6
532	7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors. 2018 , 66, 29-36	33
531	Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. 2018 , 152, 31-52	14
530	Evaluation of Kinase Inhibitor Selectivity Using Cell-based Profiling Data. 2018 , 37, e1800024	2
529	Role of Molecular Interactions and Protein Rearrangement in the Dissociation Kinetics of p38 β MAP Kinase Type-I/II/III Inhibitors. 2018 , 58, 968-981	15
528	Broad-Spectrum Regulation of Nonreceptor Tyrosine Kinases by the Bacterial ADP-Ribosyltransferase EspJ. 2018 , 9,	15
527	Exploring Selectivity of Multikinase Inhibitors across the Human Kinome. 2018 , 3, 1147-1153	13
526	Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates. 2018 , 146, 687-708	11
525	Atropisomerism in medicinal chemistry: challenges and opportunities. 2018 , 10, 409-422	104
524	Challenges and advances in the computational modeling of biological phosphate hydrolysis. 2018 , 54, 3077-3089	15
523	Interrogating Protein Phosphatases with Chemical Activity Probes. 2018 , 24, 7810-7824	9
522	A novel encystation specific protein kinase regulates chitin synthesis in <i>Entamoeba invadens</i> . 2018 , 220, 19-27	4
521	Developmental effects of the protein kinase inhibitor kenpaullone on the sea urchin embryo. 2018 , 204, 36-44	2
520	Systems biology approach deciphering the biochemical signaling pathway and pharmacokinetic study of PI3K/mTOR/p53-Mdm2 module involved in neoplastic transformation. 2018 , 7, 1	2
519	Luminescent cyclometallated platinum(II) complexes: highly promising EGFR/DNA probes and dual-targeting anticancer agents. 2018 , 5, 413-424	28

518	Protein kinase D2: a versatile player in cancer biology. 2018 , 37, 1263-1278	10
517	Pathogenesis and Management of Adiposity and Insulin Resistance in Polycystic Ovary Syndrome (PCOS). 2018 , 629-642	1
516	Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease. 2018 , 77, 139-148	23
515	ART-RRT: As-Rigid-As-Possible exploration of ligand unbinding pathways. 2018 , 39, 665-678	6
514	The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. 2018 , 133, 35-52	45
513	Endogenous Membrane Receptor Labeling by Reactive Cytokines and Growth Factors to Chase Their Dynamics in Live Cells. 2018 , 4, 1451-1464	8
512	Exploration and Comparison of the Geometrical and Physicochemical Properties of an α Allosteric Pocket in the Structural Kinome. 2018 , 58, 1094-1103	6
511	Engineered Ribosomes for Basic Science and Synthetic Biology. 2018 , 9, 311-340	28
510	TgTKL1 Is a Unique Plant-Like Nuclear Kinase That Plays an Essential Role in Acute Toxoplasmosis. 2018 , 9,	4
509	Effect of isouronium/guanidinium substitution on the efficacy of a series of novel anti-cancer agents. 2018 , 9, 735-743	5
508	3,4-Disubstituted maleimides: synthesis and biological activity. 2018 , 54, 103-113	18
507	Advances in kinome research of parasitic worms - implications for fundamental research and applied biotechnological outcomes. 2018 , 36, 915-934	6
506	Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. 2018 , 79, 46-59	37
505	Using molecular simulation to explore the nanoscale dynamics of the plant kinome. 2018 , 475, 905-921	18
504	Functional roles of magnesium binding to extracellular signal-regulated kinase 2 explored by molecular dynamics simulations and principal component analysis. 2018 , 36, 351-361	16
503	Kinome-Wide Profiling Prediction of Small Molecules. 2018 , 13, 495-499	16
502	AGC kinases, mechanisms of regulation and innovative drug development. 2018 , 48, 1-17	63
501	Evidence of vanillin binding to CAMKIV explains the anti-cancer mechanism in human hepatic carcinoma and neuroblastoma cells. 2018 , 438, 35-45	36

500	High throughput in silico identification and characterization of Plasmodium falciparum PRL phosphatase inhibitors. 2018 , 36, 3531-3540	6
499	Investigating the inhibitory potential of 2-Aminopurine metal complexes against serine/threonine protein kinases from Mycobacterium tuberculosis. 2018 , 108, 47-55	5
498	Therapeutic targeting of CK2 in acute and chronic leukemias. 2018 , 32, 1-10	53
497	Detection of post-translational modifications using solid-phase proximity ligation assay. 2018 , 45, 51-59	13
496	Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease. 2018 , 36, 4029-4044	16
495	Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. 2018 , 61, 140-157	45
494	Advances in development of new tools for the study of phosphohistidine. 2018 , 98, 291-303	24
493	Imaginative Order from Reasonable Chaos: Conformation-Driven Activity and Reactivity in Exploring Protein-Ligand Interactions. 2018 , 71, 917	
492	Computational Analysis of Kinase Inhibitors Identifies Promiscuity Cliffs across the Human Kinome. 2018 , 3, 17295-17308	16
491	Discovering de novo peptide substrates for enzymes using machine learning. 2018 , 9, 5253	36
490	Design of a Novel and Selective IRAK4 Inhibitor Using Topological Water Network Analysis and Molecular Modeling Approaches. 2018 , 23,	5
489	Coral: Clear and Customizable Visualization of Human Kinome Data. 2018 , 7, 347-350.e1	44
488	EGFR Role in Cancer: A Potential Therapeutic Target. 2018 , 225-234	1
487	Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors. 2018 , 23,	2
486	Chitosan-assisted permeabilization of ATP-biotin for live cell kinase-catalyzed biotinylation. 2018 , 65, 143-148	4
485	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. 2018 , 43, 1014-1032	86
484	In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β -Lactams To Inhibit Mycobacterial Growth. 2018 , 15, 5410-5426	13
483	In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors. 2018 , 13, 2479-2483	5

482	Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. 2018 , 15, 5678-5696	24
481	Comprehensive assessment of nine docking programs on type II kinase inhibitors: prediction accuracy of sampling power, scoring power and screening power. 2018 ,	8
480	Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation. 2018 , 8, 1412-1423	3
479	The serine/threonine protein kinase of <i>Streptococcus suis</i> serotype 2 affects the ability of the pathogen to penetrate the blood-brain barrier. 2018 , 20, e12862	10
478	Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases. 2018 , 175, 3220-3229	10
477	Introducing Targeted Cancer Treatments. 2018 , 33-63	
476	Decarboxylative cross-couplings of 2-aminopyrimidine-5-carboxylic acids. 2018 , 74, 3843-3851	3
475	Molecular Mechanisms of Gastrointestinal Signaling. 2018 , 227-315	
474	Oxindole. 2018 , 211-246	9
473	Chasing Endogenous Receptor Dynamics by Chemical Protein Labeling. 2018 , 4, 1191-1193	
472	New tools for carbohydrate sulfation analysis: heparan sulfate 2--sulfotransferase (HS2ST) is a target for small-molecule protein kinase inhibitors. 2018 , 475, 2417-2433	12
471	New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors. 2018 , 475, 2435-2455	18
470	Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer. 2018 , 37, 758-766	
469	Targeting the messengers: Serine/threonine protein kinases as potential targets for antimycobacterial drug development. 2018 , 70, 889-904	21
468	Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs. 2018 , 71, 688-701	21
467	A fluorometric method for the assay of protein kinase activity. 2018 , 557, 120-122	3
466	Dynamics of human protein kinase Aurora A linked to drug selectivity. 2018 , 7,	26
465	Cyclic Nucleotide-Directed Protein Kinases in Cardiovascular Inflammation and Growth. 2018 , 5,	3

464	Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases. 2018 , 23,	14
463	An integrative, multi-omics approach towards the prioritization of Klebsiella pneumoniae drug targets. 2018 , 8, 10755	28
462	Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. 2018 , 13, 7	39
461	Kinase-targeted cancer therapies: progress, challenges and future directions. 2018 , 17, 48	452
460	Improved strategy for the curation and classification of kinases, with broad applicability to other eukaryotic protein groups. 2018 , 8, 6808	8
459	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. 2018 , 135, 239-258	89
458	How Reactive are Druggable Cysteines in Protein Kinases?. 2018 , 58, 1935-1946	27
457	Analysis of Phosphoryl-Transfer Enzymes with QM/MM Free Energy Simulations. 2018 , 607, 53-90	8
456	Discovery of 4,5-Dihydro-1-thieno[2',3':2,3]thiopyrino [4,5-c]pyrazole-3-carboxamide Derivatives as the Potential Epidermal Growth Factor Receptors for Tyrosine Kinase Inhibitors. 2018 , 23,	5
455	DNA-encoded libraries - an efficient small molecule discovery technology for the biomedical sciences. 2018 , 399, 691-710	41
454	Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors. 2019 , 59, 3782-3793	33
453	In Silico Reoptimization of Binding Affinity and Drug-Resistance Circumvention Ability in Kinase Inhibitors: A Case Study with RL-45 and Src Kinase. 2019 , 123, 6664-6672	6
452	Phase II study of Dovitinib in recurrent glioblastoma. 2019 , 144, 359-368	16
451	Mass Spectrometry for Proteomics-Based Investigation. 2019 , 1140, 1-26	6
450	Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy. 2019 , 118, 109245	49
449	The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis. 2019 , 107-123	
448	Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine. 2019 , 125-154	1
447	The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain. 2019 , 155-183	

- 446 Discovery and Development of Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). **2019**, 239-266 1
- 445 Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. **2019**, 267-296
- 444 Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection. **2019**, 297-322
- 443 Preface. **2019**, xi-xiv
- 442 Subject Index. **2019**, 329-336
- 441 Editors' Biographies. **2019**, 323-324
- 440 Expanding the Connectivity Map Concept as the Functional Look-Up Table for Systems Biology. **2019**, 2, 201-213
- 439 Title, Copyright, Foreword. **2019**, i-v
- 438 Foreword. **2019**, ix-x
- 437 Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. **2019**, 11, 1953-1977 11
- 436 Synthetic Routes for Venetoclax at Different Stages of Development. **2019**, 1-25
- 435 Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites. **2019**, 179, 543-560.e26 31
- 434 Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. **2019**, 27-59 2
- 433 From Discovery to Market Readiness: The Research and Development of the Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib. **2019**, 61-83 1
- 432 Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis. **2019**, 185-238
- 431 Discovery and Development of the First Antibody-Antibiotic Conjugate Linker-Drug. **2019**, 85-105 2
- 430 How to design potent and selective DYRK1B inhibitors? Molecular modeling study. **2019**, 25, 41 3
- 429 Unravelling the potency of 4,5-diamino-4H-1,2,4 triazole-3-thiol derivatives for kinase inhibition using a rational approach. **2019**, 43, 1202-1215 3

428	Phosphate-guanidine interaction based fluorometric strategy for protein kinase activity sensing. 2019 , 290, 512-519	3
427	Investigation of inhibitory potential of quercetin to the pyruvate dehydrogenase kinase 3: Towards implications in anticancer therapy. 2019 , 136, 1076-1085	49
426	Modeling conformational flexibility of kinases in inactive states. 2019 , 87, 943-951	6
425	The kinase domain of CK1 can be phosphorylated by Chk1. 2019 , 83, 1663-1675	3
424	Biomimetic Lipid Membranes: Fundamentals, Applications, and Commercialization. 2019 ,	2
423	Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. 2019 , 88, 102956	10
422	Biomimetic Model Membranes as Drug Screening Platform. 2019 , 225-247	3
421	Fungal Community for Novel Secondary Metabolites. 2019 , 249-283	4
420	Ligand discrimination between active and inactive activation loop conformations of Aurora-A kinase is unmodified by phosphorylation. 2019 , 10, 4069-4076	2
419	Determination of comprehensive in silico determinants as a strategy for identification of novel PI3K inhibitors. 2019 , 30, 1761-1778	0
418	The uremic toxin p-cresol promotes the invasion and migration on carcinoma cells via Ras and mTOR signaling. 2019 , 58, 126-131	8
417	Properties of FDA-approved small molecule protein kinase inhibitors. 2019 , 144, 19-50	247
416	Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds. 2019 , 9,	20
415	Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. 2019 , 2019, 8670398	3
414	Design and synthesis of imidazolidinone derivatives as potent anti-leishmanial agents by bioisosterism. 2019 , 352, e1800290	4
413	Determination of protein phosphorylation by polyacrylamide gel electrophoresis. 2019 , 57, 93-100	15
412	Analysis of Signaling Pathways by Western Blotting and Immunoprecipitation. 2019 , 1914, 131-143	1
411	Unveiling the Kinomes of and Empowers the Discovery of New Kinase Targets and Antileishmanial Compounds. 2019 , 17, 352-361	9

410	Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones. 2019 , 9, 1676	32
409	Reading Conformational Changes in Proteins with a New Colloidal-Based Interfacial Biosensing System. 2019 , 11, 11125-11135	3
408	Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. 2019 , 20,	21
407	Profiling Transcriptional Regulation and Functional Roles of c-Jun N-Terminal Kinase. 2019 , 10, 1036	3
406	Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective. 2019 , 8,	6
405	Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. 2019 , 13, 229-243	9
404	Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation. 2019 , 1176, 538-551	22
403	Tabernaemontana catharinensis leaves effectively reduce the irritant contact dermatitis by glucocorticoid receptor-dependent pathway in mice. 2019 , 109, 646-657	9
402	Regulation of phagosome functions by post-translational modifications: a new paradigm. 2019 , 48, 73-80	7
401	Purification, modeling and structural insights of calmodulin-binding receptor like cytoplasmic kinase 2 from Oroxyllum Indicum. 2019 , 123, 704-712	3
400	Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease. 2019 , 14, 386-453	26
399	Conceptual Design of Self-Assembling Bisubstrate-like Inhibitors of Protein Kinase A Resulting in a Boronic Acid Glutamate Linkage. 2019 , 4, 775-784	7
398	Bio-guided profiling and HPLC-DAD finger printing of Atriplex lasiantha Boiss. 2019 , 19, 4	20
397	Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression. 2019 , 20, 307-320	4
396	qPhos: a database of protein phosphorylation dynamics in humans. 2019 , 47, D451-D458	24
395	Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. 2019 , 37, 510-521	9
394	Drug repurposing: progress, challenges and recommendations. <i>Nature Reviews Drug Discovery</i> , 2019 , 18, 41-58	64.1 1389
393	Post-translational modification of SOX family proteins: Key biochemical targets in cancer?. 2020 , 67, 30-38	12

392	Unity and diversity among viral kinases. 2020 , 723, 144134	2
391	Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. 2020 , 63, 884-904	54
390	Machine Learning Models for Accurate Prediction of Kinase Inhibitors with Different Binding Modes. 2020 , 63, 8738-8748	20
389	Antiproliferative activity and mode of action analysis of novel amino and amido substituted phenantrene and naphtho[2,1-b]thiophene derivatives. 2020 , 185, 111833	8
388	Plasmodium kinase disruption: new hopes for anti-malarial drug discovery. 2020 , 188, 603-604	1
387	Pharmacological Activities of Novel Chromene Derivatives as Calcium/Calmodulin Dependent Protein Kinase IV (CAMKIV) Inhibitors. 2020 , 5, 498-505	2
386	Dual-target kinase drug design: Current strategies and future directions in cancer therapy. 2020 , 188, 112025	19
385	The transition between active and inactive conformations of Abl kinase studied by rock climbing and Milestoning. 2020 , 1864, 129508	11
384	NMR-based investigation into protein phosphorylation. 2020 , 145, 53-63	5
383	Strategies for Engineering and Rewiring Kinase Regulation. 2020 , 45, 259-271	12
382	New Promise and Opportunities for Allosteric Kinase Inhibitors. 2020 , 59, 13764-13776	45
381	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. 2020 , 152, 104609	244
380	Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line. 2020 , 97, 103470	64
379	Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome. 2020 , 34, 1-10	6
378	Chemoenzymatic Semisynthesis of Proteins. 2020 , 120, 3051-3126	68
377	Concise, gram-scale synthesis of furo[2,3-]pyridines with functional handles for chemoselective cross-coupling. 2020 , 61,	1
376	Cationic Pillar[6]arene Induces Cell Apoptosis by Inhibiting Protein Tyrosine Phosphorylation Via Host-Guest Recognition. 2020 , 21,	5
375	Calcium-/Calmodulin-Dependent Protein Kinase IV (CAMKIV): A Multifunctional Enzyme and Its Role in Various Cancer: An Update. 2020 , 6, 139-147	2

374	Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia. 2020 , 56, 68-72	5
373	Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF dual inhibitors. 2020 , 104, 104260	20
372	Design, Synthesis, and Biological Evaluation of Novel 7-[1,2,4]Triazolo[3,4-][1,3,4]thiadiazine Inhibitors as Antitumor Agents. 2020 , 5, 20170-20186	6
371	Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation. 2021 , 39, 7065-7079	6
370	Investigation of cancer drug resistance mechanisms by phosphoproteomics. 2020 , 160, 105091	6
369	Deciphering the Systems Architecture of the Brain Using Molecular Can Openers. 2020 , 461-487	
368	Explicit representation of protein activity states significantly improves causal discovery of protein phosphorylation networks. 2020 , 21, 379	0
367	Identification of Potential Inhibitors of Calcium/Calmodulin-Dependent Protein Kinase IV from Bioactive Phytoconstituents. 2020 , 2020, 2094635	19
366	Oxidative Dehydrosulfurative Azolation of 3,4-Dihydropyrimidin-1H-2-thiones. 2020 , 41, 881-883	2
365	Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-]pyrimidine scaffold. 2020 , 11, 1112-1135	10
364	Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments. 2020 , 25,	5
363	Potential for Protein Kinase Pharmacological Regulation in Infections. 2020 , 21,	1
362	Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential. 2020 , 21,	10
361	KinFragLib: Exploring the Kinase Inhibitor Space Using Subpocket-Focused Fragmentation and Recombination. 2020 , 60, 6081-6094	7
360	Molecular characterization of serine/threonine protein phosphatase of Eimeria tenella. 2020 , 67, 510-520	5
359	Discovery of strong inhibitory properties of a monoclonal antibody of PKA and use of the antibody and a competitive photoluminescent orthosteric probe for analysis of the protein kinase. 2020 , 1868, 140427	1
358	Atypical ALPK2 kinase is not essential for cardiac development and function. 2020 , 318, H1509-H1515	1
357	Ruthenacarborane-Phenanthroline Derivatives as Potential Metallodrugs. 2020 , 25,	3

356	Catalytic Subunit of PKA as a Prototype of the Eukaryotic Protein Kinase Family. 2020 , 85, 409-424	2
355	Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors. 2020 , 25,	5
354	Cooperative roles of PAK1 and filamin A in regulation of vimentin assembly and cell extension formation. 2020 , 1867, 118739	8
353	Design, synthesis, molecular docking and antiproliferative activity of some novel benzothiazole derivatives targeting EGFR/HER2 and TS. 2020 , 101, 103976	16
352	Allosteric pluripotency as revealed by protein kinase A. 2020 , 6, eabb1250	15
351	Digging Deeper for the Eye Proteome in Vitreous Substructures: A High-Resolution Proteome Map of the Normal Human Vitreous Base. 2020 , 24, 379-389	2
350	Pharmacophore conjugation strategy for multi-targeting metal-based anticancer complexes. 2020 , 257-285	0
349	From Beef to Bees: High-Throughput Kinome Analysis to Understand Host Responses of Livestock Species to Infectious Diseases and Industry-Associated Stress. 2020 , 11, 765	3
348	Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. 2020 , 38, 129-143.e7	22
347	Structural and biochemical investigation of MARK4 inhibitory potential of cholic acid: Towards therapeutic implications in neurodegenerative diseases. 2020 , 161, 596-604	17
346	IPK2019: David Shugar and the genesis of the IPK conferences. 2020 , 72, 1097-1102	
345	Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead. 2020 , 10, 4248	5
344	PTPs: Degrading the Undruggable. 2020 , 63, 7508-7509	
343	Discovery of 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4: Biological evaluation and docking studies. 2020 , 353, e2000097	5
342	Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism epidermal growth factor receptor (EGFR) inhibition. 2020 , 11, 923-939	5
341	Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition. 2020 , 10, 10300	51
340	Discovery of 4-(2-(dimethylamino)ethoxy)benzohydrazide derivatives as prospective microtubule affinity regulating kinase 4 inhibitors.. 2020 , 10, 20129-20137	9
339	CK2 inhibition, lipophilicity and anticancer activity of new N1 versus N2-substituted tetrabromobenzotriazole regioisomers. 2020 , 44, 13007-13017	1

- 338 Virtual Screening of Novel Hybrid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Exploring Multiple Targeted Cancer Therapy by an In Silico Approach. **2020**, 16, 70-77
- 337 Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling. **2020**, 13, 1027-1035 11
- 336 KinCon: Cell-based recording of full-length kinase conformations. **2020**, 72, 1168-1174 7
- 335 Cataloguing the dead: breathing new life into pseudokinase research. **2020**, 287, 4150-4169 17
- 334 PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK/ERK-induced epithelial-mesenchymal transition. **2020**, 59, 467-477 7
- 333 Virtual screening in drug discovery: a precious tool for a still-demanding challenge. **2020**, 309-327 0
- 332 The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. **2020**, 155, 104725 8
- 331 Nongenetic engineering strategies for regulating receptor oligomerization in living cells. **2020**, 49, 1545-1568 25
- 330 Methods for Design of Kinase Inhibitors as Anticancer Drugs. **2019**, 7, 873 32
- 329 A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors. **2020**, 295, 2601-2613 9
- 328 Allosterische Kinaseinhibitoren – Erwartungen und Chancen. **2020**, 132, 13868-13881 0
- 327 Effects of osthol on activity, mRNA and protein expression of Cyp3a in rats in vivo. **2020**, 41, 64-71 2
- 326 Druggable exosites of the human kino-pocketome. **2020**, 34, 219-230 2
- 325 Advances and applications of stable isotope labeling-based methods for proteome relative quantitation. **2020**, 124, 115815 3
- 324 CRISPR/Cas9 mediated genetic resource for unknown kinase and phosphatase genes in Drosophila. **2020**, 10, 7383 0
- 323 Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. **2020**, 13, 402-416 12
- 322 1,2,4-Triazolin-5-thione derivatives with anticancer activity as CK1 α kinase inhibitors. **2020**, 99, 103806 6
- 321 Dipeptide Frequency of Word Frequency and Graph Convolutional Networks for DTA Prediction. **2020**, 8, 267 5

320	Mechanism of allosteric inhibition in the cGMP-dependent protein kinase. 2020 , 295, 8480-8491	14
319	Synthesis and Biochemical Evaluation of Noncyclic Nucleotide Exchange Proteins Directly Activated by cAMP 1 (EPAC1) Regulators. 2020 , 63, 5159-5184	8
318	Alkynylation-Desilylation-Alkynylation-Cycloisomerization (ADAC) Three-Component Synthesis of 2,2'-Biindolyls [Concise Synthesis of Tjipanazole I. 2021 , 13, 217-220	0
317	A historical perspective on porphyrin-based metal-organic frameworks and their applications. 2021 , 429,	43
316	10 years into the resurgence of covalent drugs. 2021 , 13, 193-210	23
315	Anti-cancer activity of two novel heterocyclic compounds through modulation of VEGFR and miR-122 in mice bearing Ehrlich ascites carcinoma. 2021 , 892, 173747	6
314	Divergent approach to the synthesis of (-)-balanol heterocycle and cis-3-hydroxypipelicolic acid based on chiral 2-aminoalkanol equivalent. 2021 , 80, 131773	2
313	E1 Enzymes as Therapeutic Targets in Cancer. 2021 , 73, 1-58	20
312	Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases. 2021 , 124, 187-223	0
311	Drug design targeting active posttranslational modification protein isoforms. 2021 , 41, 1701-1750	7
310	GraphDTA: predicting drug-target binding affinity with graph neural networks. 2021 , 37, 1140-1147	61
309	Novel Cu ²⁺ and Zn ²⁺ nanocomplexes drug based on hydrazone ligand bearings chromone and triazine moieties: Structural, spectral, DFT, molecular docking and cytotoxic studies. 2021 , 1225, 129158	13
308	Nanostructured Materials and their Applications. 2021 ,	
307	Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies. 2021 , 12, 34-45	1
306	Kinome-Wide Activity Classification of Small Molecules by Deep Learning.	
305	Dual roles of ATP-binding site in protein kinases: Orthosteric inhibition and allosteric regulation. 2021 , 124, 87-119	3
304	Targeting respiratory complex I [molecular mechanism and drug design. 2021 , 327-340	
303	Two-Dimensional Metalloporphyrinic Framework Nanosheet-Based Dual-Mechanism-Driven Ratiometric Electrochemiluminescent Biosensing of Protein Kinase Activity.. 2021 , 4, 1616-1623	6

302	Emerging roles of DYRK2 in cancer. 2021 , 296, 100233	7
301	State-selective frustration as a key driver of allosteric pluripotency. 2021 , 12, 11565-11575	5
300	Versatile small molecule kinase assay through real-time, ratiometric fluorescence changes based on a pyrene-DPA-Zn complex.. 2021 , 11, 10375-10380	2
299	Development of a TSR-Based Method for Protein 3-D Structural Comparison With Its Applications to Protein Classification and Motif Discovery. 2020 , 8, 602291	0
298	Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.	0
297	Protein arginine phosphorylation in organisms. 2021 , 171, 414-422	6
296	Equilibrium solubility determination, Hansen solubility parameters and solution thermodynamics of cabozantinib malate in different monosolvents of pharmaceutical importance. 2021 , 324, 115146	5
295	Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945. 2021 , 10,	2
294	Selective Enrichment of Histidine Phosphorylated Peptides Using Molecularly Imprinted Polymers. 2021 , 93, 3857-3866	12
293	Kinase Signaling in Dendritic Development and Disease. 2021 , 15, 624648	4
292	A Curious Case for Development of Kinase Inhibitors as Antigiardiasis Treatments Using Advanced Drug Techniques. 2021 , 7, 943-947	1
291	Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action. 2021 , 22,	4
290	Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. 2021 , 36, 127788	4
289	Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors. 2021 , 26,	7
288	Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). 2021 , 165, 105422	15
287	Rapid Identification of Inhibitors and Prediction of Ligand Selectivity for Multiple Proteins: Application to Protein Kinases. 2021 , 125, 2288-2298	0
286	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. 2021 , 165, 105463	107
285	Organofluorine Hydrazone Derivatives as Multifunctional Anti-Alzheimer's Agents with CK2 Inhibitory and Antioxidant Features. 2021 , 16, 1927-1932	4

284	Recent advances in biological activities of rhodium complexes: Their applications in drug discovery research. 2021 , 216, 113308	13
283	Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. 2021 , 28, 27	25
282	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. 2021 , 12, 2383	9
281	Next-generation yeast-two-hybrid analysis with Y2H-SCORES identifies novel interactors of the MLA immune receptor. 2021 , 17, e1008890	2
280	Enzymes as Drug Targets. 1-51	
279	A survey of the kinome pharmacopeia reveals multiple scaffolds and targets for the development of novel anthelmintics. 2021 , 11, 9161	1
278	US FDA-Approved Small-Molecule Kinase Inhibitors for Cancer Therapy. 1-65	
277	Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. 2021 , 21, 111-132	1
276	Analysis of sunitinib malate, a multi-targeted tyrosine kinase inhibitor: A critical review. 2021 , 163, 105926	2
275	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. 2021 , 215, 113299	6
274	Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. 2021 , 22, 357-371	7
273	Classical MD and metadynamics simulations on back-pocket binders of CDK2 and VEGFR2: a guidepost to design novel small-molecule dual inhibitors. 2021 , 1-12	0
272	Kinase Inhibitors as Underexplored Antiviral Agents. 2021 ,	7
271	Protein kinases in <i>Toxoplasma gondii</i> . 2021 , 51, 415-429	3
270	Kinome analyses of <i>Candida albicans</i> , <i>C. parapsilosis</i> and <i>C. tropicalis</i> enable novel kinases as therapeutic drug targets in candidiasis. 2021 , 780, 145530	1
269	Whole transcriptome RNA-seq reveals key regulatory factors involved in type 2 diabetes pathology in peripheral fat of Asian Indians. 2021 , 11, 10632	1
268	Approach in Improving Potency and Selectivity of Kinase Inhibitors: Allosteric Kinase Inhibitors. 2021 , 21, 991-1003	3
267	Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations. 2021 , 110, 104748	20

266	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 551-569	64.1	109
265	Self-assembly of an anion receptor with metal-dependent kinase inhibition and potent in vitro anti-cancer properties. 2021 , 12, 3898		1
264	Molecular Docking, synthesis, anticancer assessment and ADME study of naproxen containing imidazole ring derivatives. 2021 ,		
263	Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma. 2021 , 64, 11129-11147		1
262	Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma. 2021 , 12, 691769		1
261	Exploration of 7-azaindole-coumaranone hybrids and their analogues as protein kinase inhibitors. 2021 , 343, 109478		0
260	Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA). 2021 , 21, 789		0
259	Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment. 2021 , 26, 2680-2698		0
258	Identification and Phenotypic Characterization of Hsp90 Phosphorylation Sites That Modulate Virulence Traits in the Major Human Fungal Pathogen. 2021 , 11, 637836		4
257	Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling. 2021 , 11, 676948		1
256	Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets. 2021 , 81, 5765-5776		3
255	Evaluation of small molecule kinase inhibitors as novel antimicrobial and antibiofilm agents. 2021 , 98, 1038-1064		0
254	Quantitative phosphoproteomics reveals regulatory state dependent efficacy of chemical Cdk1 inhibition and distinct Cdk5 complexes as novel Wee1 substrates.		
253	Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer. 2021 , 13,		
252	A rotamer relay information system in the epidermal growth factor receptor-drug complexes reveals clues to new paradigm in protein conformational change. 2021 , 19, 5443-5454		
251	Multiscale computational study of ligand binding pathways: Case of p38 MAP kinase and its inhibitors. 2021 , 120, 3881-3892		1
250	PIIKA 2.5: Enhanced quality control of peptide microarrays for kinome analysis. 2021 , 16, e0257232		1
249	Kinase Inhibitor Scaffold Hopping with Deep Learning Approaches. 2021 , 61, 4900-4912		2

248	Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase. 2021 , 61, 5234-5242	3
247	Recent Advances about the Applications of Click Reaction in Chemical Proteomics. 2021 , 26,	2
246	Improvements in the Synthesis of the Third-Generation EGFR Inhibitor Osimertinib. 2021 , 104, e2100066	
245	Cytotoxic potential of Rheum emodi capped silver nanoparticles and In silico study of human CDK-4/6 proteins with hydroxyanthraquinones. 2021 , 98, 100136	0
244	Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders. 2021 , 86, 110070	0
243	Discovery of thiazolidin-4-one analogue as selective GSK-3 β inhibitor through structure based virtual screening. 2021 , 52, 128375	
242	Design, synthesis, anticancer evaluation and molecular docking study of novel 2,4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors. 2022 , 1247, 131285	3
241	Logical synthetic strategies and structure-activity relationship of indolin-2-one hybrids as small molecule anticancer agents: An overview. 2022 , 1247, 131280	2
240	Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. 2021 , 21, 55-69	1
239	High-Throughput Phosphoproteomics from Formalin-Fixed, Paraffin-Embedded Tissues. 2012 , 4, 161-175	3
238	Quantification of protein kinase enzymatic activity in unfractionated cell lysates using CSox-based sensors. 2014 , 6, 135-156	11
237	Structural Bases of Protein Kinase CK2 Function and Inhibition. 1-75	3
236	Protein Kinase CK2: At the Crossroads of Pathways Controlling Cell Proliferation and Survival. 169-189	2
235	Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. 2020 , 147, 3160-3167	11
234	Learning and memory. 2005 , 1-34	2
233	Gene Arrays, Cell Lines, Stem Cells, and Sensory Regeneration in Mammalian Ears. 257-307	4
232	Enhanced prediction of conformational flexibility and phosphorylation in proteins. 2010 , 680, 307-19	8
231	Protein Phosphatases in the Brain: Regulation, Function and Disease. 2011 , 233-257	1

230	Molecules with Potential for Cancer Therapy in the Developing World: Dibenzyl Trisulfide (DTS). 2012 , 273-278	3
229	Identification of Direct Kinase Substrates via Kinase Assay-Linked Phosphoproteomics. 2016 , 1355, 263-73	5
228	Using Bioluminescent Kinase Profiling Strips to Identify Kinase Inhibitor Selectivity and Promiscuity. 2016 , 1360, 59-73	5
227	Protein Kinase Selectivity Profiling Using Microfluid Mobility Shift Assays. 2016 , 1439, 143-57	3
226	Probing Protein Kinase-ATP Interactions Using a Fluorescent ATP Analog. 2017 , 1647, 171-183	6
225	Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia. 2008 , 161-187	3
224	The peptide microarray-based assay for kinase functionality and inhibition study. 2009 , 570, 329-37	3
223	Targeting the purinome. 2009 , 575, 47-92	13
222	Quantification of protein kinase activities by LC-MS. 2010 , 658, 325-37	1
221	Phos-tag Affinity Electrophoresis for Protein Kinase Profiling. 2012 , 13-34	3
220	Synthesis and biological evaluation of selected 7-azaindole derivatives as CDK9/Cyclin T and Haspin inhibitors. 2020 , 29, 1449-1462	3
219	Discovery of Inactive Conformation-Selective Kinase Inhibitors by Utilizing Cascade Assays. 2017 , 56, 4449-4456	5
218	CHAPTER 6: Sample Preparation and Profiling: Probing the Kinome for Biomarkers and Therapeutic Targets: Peptide Arrays for Global Phosphorylation-Mediated Signal Transduction. 2013 , 162-195	5
217	Functions and regulation of the serine/threonine protein kinase CK1 family: moving beyond promiscuity. 2020 , 477, 4603-4621	5
216	Hepatotoxicity of FDA-approved small molecule kinase inhibitors. 2021 , 20, 335-348	4
215	Repurposed kinase inhibitors and β -lactams as a novel therapy for antibiotic resistant bacteria.	3
214	The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro. 2020 ,	19
213	Identification of COVID-19-relevant transcriptional regulatory networks and associated kinases as potential therapeutic targets.	1

212	Coral: Clear and customizable visualization of human kinome data.	0
211	GraphDTA: Predicting drug-target binding affinity with graph neural networks.	28
210	Inhibition of IRF5 hyperactivation protects from lupus onset and severity. 2020 , 130, 6700-6717	18
209	(R)-Roscovitine (CYC202, Seliciclib). 2006 , 187-225	9
208	Structural and functional diversity of the microbial kinome. 2007 , 5, e17	205
207	Phenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization. 2010 , 5, e14272	8
206	Statistical properties and robustness of biological controller-target networks. 2012 , 7, e29374	11
205	Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors. 2013 , 8, e53668	6
204	Protein kinase C-dependent signaling controls the midgut epithelial barrier to malaria parasite infection in anopheline mosquitoes. 2013 , 8, e76535	20
203	Analysis of the Protein phosphotome of Entamoeba histolytica reveals an intricate phosphorylation network. 2013 , 8, e78714	8
202	A novel quantitative kinase assay using bacterial surface display and flow cytometry. 2013 , 8, e80474	15
201	Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell lines. 2014 , 9, e95688	1
200	Control of asymmetric Hopfield networks and application to cancer attractors. 2014 , 9, e105842	11
199	Pharmacokinetics of Dasatinib. 2019 , 120, 52-63	7
198	Application of drug-metal ion interaction principle in conductometric determination of imatinib, sorafenib, gefitinib and bosutinib. 2020 , 18, 798-807	3
197	Mitochondrial protein import under kinase surveillance. 2014 , 1, 51-57	9
196	Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. 2014 , 5, 3697-710	79
195	Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. 2017 , 8, 111190-111212	21

194	MicroRNA-based regulation of Aurora A kinase in breast cancer. 2020 , 11, 4306-4324	4
193	CoralP: Flexible visualization of the human phosphatome. 2019 , 4,	2
192	Emerging role of MAP kinase pathways as therapeutic targets in COPD. 2006 , 1, 137-50	44
191	Inhibitors of Serine/Threonine Protein Phosphatases: Biochemical and Structural Studies Provide Insight for Further Development. 2019 , 26, 2634-2660	9
190	An Update on the Association of Protein Kinases with Cardiovascular Diseases. 2019 , 25, 174-183	11
189	A Comparative Analysis and Review of lysyl Residues Affected by Posttranslational Modifications. 2015 , 16, 128-38	10
188	Recent Development of Machine Learning Methods in Microbial Phosphorylation Sites. 2020 , 21, 194-203	4
187	Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment. 2020 , 20, 444-465	8
186	Cheminformatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors. 2016 , 16, 1452-62	3
185	Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors. 2019 , 19, 467-485	8
184	Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review. 2020 , 20, 1124-1135	13
183	Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity. 2020 , 16, 270-280	4
182	Protein kinases and associated pathways in pluripotent state and lineage differentiation. 2014 , 9, 366-87	6
181	Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase. 2010 , 4, 27-33	2
180	Phenotypic proteomic profiling identifies a landscape of targets for circadian clock-modulating compounds. 2019 , 2,	9
179	Melanoma: oncogenic drivers and the immune system. 2015 , 3, 265	15
178	Bioinformatics. 2018 , 26-47	3
177	Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. 2011 , 19, 371-389	6

176	The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. 2011 , 10, 32	42
175	Indolin-2-Ones in Clinical Trials as Potential Kinase Inhibitors: A Review. 2012 , 03, 62-71	37
174	Chemical kinomics: a powerful strategy for target deconvolution. 2010 , 43, 711-9	6
173	Pharmacophore approaches in protein kinase inhibitors design. 2014 , 3, 162	5
172	Molecular docking studies of benzimidazopyrimidine and coumarin substituted benzimidazopyrimidine derivatives: As potential human Aurora A kinase inhibitors. 2014 , 10, 288-92	9
171	Inhibition of protein kinases by proton pump inhibitors: computational screening and in vitro evaluation. 2021 , 30, 2266-2276	0
170	Tyrosine kinases: complex molecular systems challenging computational methodologies. 2021 , 94, 1	2
169	Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design. 2021 , 50, 116457	1
168	Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation. 2021 , 117, 105420	0
167	Drug discovery opportunities. 2003 , 1-10	
166	Bioinformatics: Protein Tyrosine Phosphatases. 2003 , 659-670	
165	Homogeneous High-Throughput Screening (HTS) Assays for Serine/Threonine Kinases Using -Galactosidase Enzyme Fragment Complementation. 2006 , 89-102	
164	Overview of molecular target-based drugs. 2006 , 21, 18-23	2
163	Development of CDK Inhibitors as Anticancer Agents. 2006 , 121-142	
162	How drugs act: molecular aspects. 2007 , 24-53	
161	Structure Prediction of Membrane Proteins. 2007 , 65-108	
160	Anti-Cancer Effect of Indirubin-3'-Monoxime for Human Laryngeal Carcinoma. 2009 , 6, 27-34	
159	Pharmacologic Principles. 2010 , 159-199	

- 158 Pathogenesis and Management of Adiposity and Insulin Resistance in PCOS: Prevention and Treatment of the Metabolic Disease Components. **2010**, 357-367
- 157 Chemical and Drug Receptor Interactions. **2010**, 115-125
- 156 Protein Kinase Inhibitors in Drug Discovery. 1
- 155 Readout Present and Near Future. **2010**, 221-251
- 154 Rheumatoid Arthritis. **2011**, 55-74
- 153 Cardiology-In-Depth Look: Kinases as Therapeutic Targets in the Heart.
- 152 How drugs act. **2012**, 20-48
- 151 CHAPTER 7:Discovery of the Serenex Hsp90 Inhibitor, SNX5422. **2013**, 198-212
- 150 Proteomic Analysis of Posttranslational Modifications. 87-116
- 149 Melatonin and Malaria: Therapeutic Avenues. **2014**, 183-192
- 148 Protein Kinases and Caspases: Bidirectional Interactions in Apoptosis. 85-114
- 147 Effect of Physiochemical Properties on Classification Algorithms for Kinases Family. **2016**, 47-57
- 146 Encyclopedia of Signaling Molecules. **2016**, 1-9
- 145 QSAR STUDIES ON PYRAZOLO [1, 5-A] PYRIMIDINE-BASED PIM-1 KINASE INHIBITORS. **2016**, 53, 12-19 2
- 144 Evaluation of 6-chloro-N-[3,4-disubstituted-1,3-thiazol-2(3H)-ylidene]-1,3-benzothiazol-2-amine Using Drug Design Concept for Their Targeted Activity Against Colon Cancer Cell Lines HCT-116, HCT15, and HT29. **2017**, 23, 1146-1155 1
- 143 Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents. **2018**, 347-417 1
- 142 Chapter 9:Paramagnetic NMR in Drug Discovery. **2018**, 258-282
- 141 Encyclopedia of Signaling Molecules. **2018**, 1438-1446

140 Dynamics of human protein kinases linked to drug selectivity.

139 New tools for carbohydrate sulphation analysis: Heparan Sulphate 2-O-sulphotransferase (HS2ST) is a target for small molecule protein kinase inhibitors.

138 New tools for evaluating protein tyrosine sulphation: Tyrosyl Protein Sulphotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors.

137 . 2019,

136 CoralP: Flexible visualization of the human phosphatome.

135 Assessment of mitogen-activated protein kinases as therapeutic targets for the treatment of babesiosis and theileriosis. **2020**, 44, 702-713

134 Genome-Wide Mapping of Cisplatin Damaged Gene Loci.

133 A Survey of the Kinome Pharmacopeia Reveals Multiple Scaffolds and Targets for the Development of Novel Anthelmintics.

132 Understanding the impact of anticancer halogenated inhibitors and various functional groups (X = Cl, F, CF, CH, NH, OH, H) of casein kinase 2 (CK2). **2020**, 1-17 1

131 Computational Approaches for Drug Target Identification. **2020**, 163-185 1

130 Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs. **2020**, 115, e200229 3

129 CHAPTER 8:Chemical Probes for Kinases. **2020**, 182-213

128 Understanding the mechanism of action of pyrrolo[3,2-]quinoxaline-derivatives as kinase inhibitors. **2020**, 11, 665-675 0

127 Protein Phosphorylation Affects Meat Color. **2020**, 23-47

126 Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors. **2020**, 1

125 Nanowire Nanosensors for Biological and Medical Application. **2021**, 385

124 A novel Hsp90 phospho-switch modulates virulence in the major human fungal pathogen *Candida albicans*. 1

123 Correction of the Taxonomic Composition of Human Gut Microbiota: Serine-Threonine Protein Kinases as Biotargets. **2020**, 10, 495-506

122	NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. 2007 , 2, 93-106	6
121	Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system. 2010 , 21, 9-17	7
120	Protein tyrosine kinase panel as a tool for anticancer drug design. 2009 , 1, 84-8	1
119	New Test System for Serine/Threonine Protein Kinase Inhibitors Screening: E. coli APHVIII/Pk25 design. 2010 , 2, 110-21	
118	Computational methods and opportunities for phosphorylation network medicine. 2014 , 3, 266-278	6
117	EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives. 2014 , 13, 573-85	9
116	Comparative analysis of the human and zebrafish kinomes: focus on the development of kinase inhibitors. 2015 , 10, 49-75	2
115	Discerning Tyrosine Phosphorylation from Multiple Phosphorylations Using a Nanofluidic Logic Platform. 2021 , 93, 16113-16122	0
114	Electrochemical biosensors based on peptide-kinase interactions at the kinase docking site.	
113	Molecularly Imprinted and Cladded Nanoparticles Provide Better Phosphorylation Recognition. 2021 , 93, 16194-16202	0
112	Synthesis, In Vitro and In Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors. 2021 , 22,	2
111	Synthesis of illudalic acid and analogous phosphatase inhibitors. 2021 ,	1
110	Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.. 2022 , 27,	0
109	N.E.Br Manifests Extraction Medium Reliant Disparity in Phytochemical and Pharmacological Analysis.. 2021 , 26,	1
108	Tracking mutation and drug-driven alterations of onco kinase conformations. 1	0
107	An overview of in silico methods used in the design of VEGFR-2 inhibitors as anticancer agents. 2020 ,	
106	Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update.. 2021 , 106037	22
105	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. 2022 ,	3

104	Evaluation of New Antimicrobial Agents Based on (1-Indol-3-yl)methylammonium Salts: Activity, Toxicity, Suppression of Experimental Sepsis in Mice.. 2022 , 15,	1
103	Phosphoproteomic profiling of influenza virus entry reveals infection-triggered filopodia induction counteracted by dynamic cortactin phosphorylation.. 2022 , 38, 110306	1
102	Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.. 2022 , 14,	2
101	Pharmacophore modeling, Virtual screening, Molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach. 2022 , 132531	1
100	Divergent allostery reveals critical differences between structurally homologous regulatory domains of Plasmodium falciparum and human protein kinase G.. 2022 , 101691	1
99	Reactivity-based chemical-genetic study of protein kinases.	0
98	C5-Iminosugar modification of casein kinase 1 β lead 3-(4-fluorophenyl)-5-isopropyl-4-(pyridin-4-yl)isoxazole promotes enhanced inhibitor affinity and selectivity.. 2022 , e2100497	
97	CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition.. 2022 , 9, 834814	1
96	Synthesis, Assessment of Antineoplastic Activity and Molecular Docking of Novel 2-Thioxo-oxazolidin-4-one Derivatives.. 2022 ,	
95	Shining Light on Protein Kinase Biomarkers with Fluorescent Peptide Biosensors.. 2022 , 12,	
94	ChemInformatics Model Explorer (CIME): exploratory analysis of chemical model explanations.. 2022 , 14, 21	0
93	Tackling polypharmacology of kinase inhibitors by transcription factor activity profiling.	0
92	A Review: Natural and Synthetic Compounds Targeting and Its Biological Membrane.. 2022 , 12,	0
91	Design and development of photoswitchable DFG-Out RET kinase inhibitors.. 2022 , 234, 114226	1
90	Active Site Sequence Representations of Human Kinases Outperform Full Sequence Representations for Affinity Prediction and Inhibitor Generation: 3D Effects in a 1D Model.. 2021 ,	1
89	Attention-enhanced Graph Cross-convolution for Protein-Ligand Binding Affinity Prediction. 2021 ,	
88	Identification of transcriptional regulatory network associated with response of host epithelial cells to SARS-CoV-2.. 2021 , 11, 23928	
87	Introductory Chapter: Protein Kinases as Promising Targets for Drug Design against Cancer.	3

- 86 Identification of potent inhibitors of NEK7 protein using a comprehensive computational approach.. **2022**, 12, 6404 4
- 85 Towards Kinase Inhibitor Therapies for Fragile X Syndrome: Tweaking Twists in the Autism Spectrum Kinase Signaling Network.. **2022**, 11, 0
- 84 Lockdown, a selective small-molecule inhibitor of the integrin phosphatase PPM1F, blocks cancer cell invasion.. **2022**, 0
- 83 Table_1.XLSX. **2020**,
- 82 Table_2.XLSX. **2020**,
- 81 Table_3.XLSX. **2020**,
- 80 Table_4.XLSX. **2020**,
- 79 Image_1.tif. **2019**,
- 78 Presentation_1.pdf. **2019**,
- 77 Table_2.csv. **2019**,
- 76 Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails.. **2022**, 37, 1257-1277
- 75 Recent Progress in Fluorescent Chemosensors for Protein Kinases.. **2022**,
- 74 New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activity: Design, molecular modeling and synthesis.
- 73 Discovery of pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations. **2022**, 12, 14865-14882 0
- 72 Compounds co-targeting kinases in axon regulatory pathways promote regeneration and behavioral recovery after spinal cord injury in mice.. **2022**, 114117 0
- 71 Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.. **2022**, 1
- 70 Identification of pan-kinase-family inhibitors using graph convolutional networks to reveal family-sensitive pre-moieties. **2022**, 23, 0
- 69 Progress in DNA Aptamers as Recognition Components for Protein Functional Regulation.

68	Kinome Analysis to Define Mechanisms of Adjuvant Action: PCEP Induces Unique Signaling at the Injection Site and Lymph Nodes. 2022 , 10, 927	0
67	Posttranslational Regulation of Inflammasomes, Its Potential as Biomarkers and in the Identification of Novel Drugs Targets. 10,	1
66	Luminescent lanthanide probes for inorganic and organic phosphates.	0
65	Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study. 2022 , 14, 1216	1
64	Maximizing the integration of virtual and experimental screening in hit discovery. 1-12	
63	PeSTK db a comprehensive data repository of Probiotic Serine Threonine kinases. 2022 , 9,	0
62	Can Nanomedicinal Approaches Provide an Edge to The Efficacy of Tyrosine Kinase Inhibitors?. 2022 , 29,	1
61	Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics. 9,	0
60	STAP-2 Is a Novel Positive Regulator of TCR-Proximal Signals. 2022 , 209, 57-68	0
59	Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity. 2022 , 37, 1957-1973	1
58	Recent Advances in Synthesis and the Anticancer Activity of Benzothiazole Hybrids as Anticancer Agents. 2022 , 105-166	
57	Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation. 2022 , 176, 106249	
56	Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth. 2005 , 11, 1336-1341	16
55	Recent advances in targeting protein kinases and pseudokinases in cancer biology. 10,	1
54	Drug-Target Affinity Prediction Based on Multi-channel Graph Convolution. 2022 , 533-546	
53	Emerging Role of Structural and Systems Biology in Anticancer Therapeutics. 2022 , 97-114	
52	Targeted cancer phototherapy using phthalocyanine-anticancer drug conjugates.	
51	Intrinsically Fluorescent Anti-Cancer Drugs. 2022 , 11, 1135	1

- 50 A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. 0
- 49 Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. **2022**, 13, 1426 0
- 48 Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety. **2022**, 65, 10898-10919 2
- 47 Functional inactivation of Plasmodium falciparum glycogen synthase kinase GSK3 modulates erythrocyte invasion and blocks gametocyte maturation. **2022**, 102360 0
- 46 Posttranslational modifications of platelet adhesion receptors. **2022**, 183, 106413 1
- 45 Nicotinonitrile-derived apoptotic inducers: Design, synthesis, X-ray crystal structure and Pim kinase inhibition. **2022**, 129, 106126 2
- 44 Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer. **2022**, 243, 114704 1
- 43 Therapeutic peptides targeting protein kinase: progress, challenges, and future directions, featuring cancer and cardiovascular disease. **2022**, 333-356 0
- 42 BindingSiteAugmentedDTA: Enabling A Next-Generation Pipeline for Interpretable Prediction Models in Drug-Repurposing. 0
- 41 A perspective study on the RTK, PI3K, B-Raf, CDK and the multi-protein targeting in medicinal chemistry. 0
- 40 Phosphorylation, compartmentalization, and cardiac function. 0
- 39 Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. 12, 0
- 38 An insight on the different synthetic routes for the facile synthesis of O/S-donor carbamide/thiocarbamide analogs and their miscellaneous pharmacodynamic applications. 1-58 0
- 37 Molecularly Imprinted and Cladded Nanotags Enable Specific SERS Bioimaging of Tyrosine Phosphorylation. 0
- 36 Pyrazolo[3,4-d]pyrimidine scaffold: A review on synthetic approaches and EGFR and VEGFR inhibitory activities. 0
- 35 We will ROCK you? The role of Rho kinase inhibitors in eye care. **2020**, 2020, 8191-1 0
- 34 Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases. **2022**, 27, 7124 0
- 33 Nature-Based Computing Bioinformatics Approaches in Drug Discovery Against Promising Molecular Targets Carbonic Anhydrases and Serine/Threonine Kinases for Cancer Treatment. **2023**, 309-328 0

32	Molecular mechanisms of hormonal activity. I. receptors. neuromediators. systems with second messengers. 2005 , 70, 24-39	0
31	WEMURAFENIB JAKO SELEKTYWNY INHIBITOR KINAZY SERONINOWO-TREONINOWEJ B-RAF STOSOWANY W LECZENIU CZERNIAKA. 2016 , 14, 52-56	0
30	Properties of FDA-approved Small Molecule Protein Kinase Inhibitors: A 2023 Update. 2022 , 106552	6
29	Curcumin based pyrazole-thiazole hybrids as antiproliferative agents: Synthesis, pharmacokinetic, photophysical properties, and docking studies. 2023 , 1275, 134633	0
28	KID: A Kinase-Focused Interaction Database and Its Application in the Construction of Kinase-Focused Molecule Databases. 2022 , 62, 6022-6034	1
27	A pan-cancer analysis of the FAT1 in human tumors. 2022 , 12,	0
26	Mechanotransduction regulates inflammation responses of epicardial adipocytes in cardiovascular diseases. 13,	0
25	MSC-1186, a Highly Selective Pan-SRPK Inhibitor Based on an Exceptionally Decorated Benzimidazole-Pyrimidine Core.	0
24	Investigating the conformational landscape of AlphaFold2-predicted protein kinase structures.	0
23	PTMint Database of Experimentally Verified PTM Regulation on Protein-Protein Interaction.	1
22	Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studies. 1-12	0
21	Targets mapped for almost all human kinase enzymes.	0
20	Beyond sequence: Structure-based machine learning. 2023 , 21, 630-643	0
19	Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment. 2023 , 15, 215	0
18	Inhibition of Abl Kinase by Imatinib Can Rescue the Compromised Barrier Function of 22q11.2DS Patient-iPSC-Derived BloodBrain Barriers. 2023 , 12, 422	0
17	What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?. 2023 , 12, 166	0
16	Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review). 2023 , 49,	0
15	TgTKL4 Is a Novel Kinase That Plays an Important Role in Toxoplasma Morphology and Fitness.	0

- 14 New benzylidene festooned thiazolidinone-coumarin molecular hybrids targeting Human Breast adenocarcinoma cells: Design, synthesis, SAR, molecular Modelling and biological evaluation as CDK2 inhibitors. **2023**, 1285, 135453
- 13 Design, synthesis and cytotoxic evaluation of novel bis-thiazole derivatives as preferential Pim1 kinase inhibitors with in vivo and in silico study. **2023**, 38,
- 12 Utilization of kinase inhibitors as novel therapeutic drug targets: A review. **2022**, 30, 221-230
- 11 Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity. **2023**, 24, 3216
- 10 Synthesis and Biological Evaluation of Benzo[d] thiazolyl-Sulfonyl-Benzo[4,5]isothiazolo [2,3-c][1,2,3] triazole Derivatives as EGFR Targeting Anticancer Agents. **2023**, 8,
- 9 Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study. **2023**, 20,
- 8 Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. **2023**, 15, 568
- 7 Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. **2023**, 66, 3135-3172
- 6 Cancer proteomics: An overview. **2023**, 1-30
- 5 Extended-sampling QM/MM simulation of biochemical reactions involving P_N bonds. **2023**, 25, 9824-9836
- 4 Drug-target affinity prediction method based on consistent expression of heterogeneous data. **2022**,
- 3 Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. **2023**, 106774
- 2 Target proteins profiling of irreversible kinase inhibitor pelitinib and discovery of degradation of PRDX4 by label free chemoproteomics. **2023**, 230, 115398
- 1 MKK4 Inhibitors Recent Development Status and Therapeutic Potential. **2023**, 24, 7495